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ABSTRACT  
 
Although in the last decades there has been a growing interest in neurodegenerative diseases, 
there are still no effective therapies. Some of these diseases are considered protein misfolding 
disorders (PCDs), since they are mainly caused by a conformational change of a native protein 
into a disease-associated one, that can aggregate and form an infective seed; Alzheimer’s 
disease with Ab and Tau proteins, Parkinson’s disease with a-synuclein, and prion diseases 
with prion protein. 
Recently, transmissible spongiform encephalopathies (TSEs), also known as prion diseases, 
have been considered as a prototype of neurodegenerative diseases for their ability to be 
sporadic, inherited and also infectious. Indeed, the infectivity was long thought to belong 
exclusively to prion diseases, but in the last years accumulating evidence suggest that other 
proteins follow a similar mechanism of seed self-propagation and cell-to-cell spreading in vitro 
and in vivo. 
TSEs are mainly characterized by vacuolation, neuronal loss, cognitive and motor 
impairments. They include kuru, Creutzfeldt-Jacob disease, Gerstmann Sträussler-Scheinker 
syndrome and fatal familial insomnia in human, bovine spongiform encephalopathy in cattle, 
scrapie in sheep and chronic wasting disease in elk and deer. The etiology agent is the scrapie 
prion protein (PrPSc), the abnormal, misfolded form of the cellular prion protein (PrPC). The 
normal protein is anchored to the cell surface through a C-terminal moiety of 
glycophosphatidyl-inositol (GPI). Even though the two isoforms share the same primary 
sequence, they have several different aspects: PrPC is rich in a-helices, is soluble and protease 
K (PK) sensitive; while the PrPSc has a high level of b-sheets, is insoluble and partially PK 
resistant. 
The molecular mechanism underlying the conversion of PrPC to PrPSc is still not completely 
understood. Several studies in literature focus on the ability of small molecules to inhibit the 
conversion by either binding the PrPC or blocking the PrPSc aggregation. The majority of 
compounds screened for this action were already used as antivirals, antimalarials, antifungals 
and antidepressants. Drug repositioning is a strategy that uses known compounds to treat new 
diseases. By using this approach quinacrine (antimalarial), Pentosan Polysulfate (heparin 
mimetic), Doxycycline (antibiotic) and Flupirtine (analgesic) were tested in human clinical 
trials, unfortunately without the expected results. Other approaches applied to develop anti-
prion therapies are medicinal chemistry, multi-target approaches and in silico methods. 
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In drug screening, the in silico method is useful to increase the discovery speed of new drugs, 
thus reducing costs and lab work. In particular, we developed a quantitative structure-activity 
relationship model (QSAR) and by using it performed a virtual screening of some purchasable 
compounds. With the help of the QSAR model, we obtained a library of 10 molecules with a 
predicted IC50 in the nanomolar range. Immortalized neuroblastoma (N2a) and hypothalamic 
(GT1) mouse cell lines chronically infected with prions were used to assess the cell viabilty of 
the library and to measure the anti-prion infectivity.  
After performing western blot analysis and Real-Time Quaking-Induced Conversion (RT-
QuIC) assay, compound 1 emerged as the most promising molecule, since it was able to 
completely cure N2a-RML cells from PrPSc, either after acute or chronic treatments. 
Additionally, we designed a competitional assay, which shows that compound 1 blocks prion 
conversion by binding to the cellular prion protein. These results make this molecule an 
interesting and promising therapeutic tool for prion diseases. 
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CHAPTER I 
 
 
Introduction 
 
 
1.1 Neurodegenerative diseases 
 
Over the last decades different disorders caused by protein misfolding have been studied and 
grouped together under the name of protein conformational disorders (PCDs). Many of these 
diseases are neurodegenerative disorders, such as Alzheimer’s disease (AD), transmissible 
spongiform encephalopathies (TSEs), Huntington’s disease (HD), Parkinson’s disease (PD), 
and amyotrophic lateral sclerosis (ALS) [1].  
The neurodegenerative diseases can be caused by mutations or sporadic events, in any case the 
onset of the disorder increases with aging. These age-related pathologies have high societal 
costs and lead to a dramatic loss of life quality for patients and caregivers. Nowadays, there is 
still no cure for any of these disorders. Furthermore, 45 million people worldwide are affected 
by some form of neurodegeneration, and data from 2015 report of World Health Organization 
(WHO) claims that in 2030 the affected are expected to reach 76 million.  
Neurodegenerative diseases are debilitating conditions that affect the nervous system resulting 
in progressive degeneration and death of nerve cells. This causes many different symptoms, 
such as problems with movement (tremor, ataxia, balance impairment) and mental functions -
(apathy, insomnia, dementia) [2]. 
Each neurodegenerative disease is caused by specific misfolded protein. For example, amyloid-
β (Aβ) and tau as neurofibrillary tangles (NFTs) in AD [3, 4], α-synuclein (α-syn) in PD [5], 
Cu/Zn superoxide dismutase (SOD1) and TAR DNA-binding protein 43 (TDP-43) in ALS [6, 
7], prions (PrPSc) in prion diseases, also known as TSEs [8], and others (Table 1). 
The protein folding determines the three-dimensional (3D) structure, given by amino acid 
sequence, and the biological function of a protein. The protein misfolding is due to a lack of a 
correct three-dimensional structure. This conformational change in the secondary or tertiary 
structure, but not in the primary, can lead the protein to toxicity and/or loss of its biological 
activity. Misfolded proteins are rich in β-sheets, that is a specific conformation which consist of 
alternating peptide-pleated strands linked by hydrogen bonding between the amino and the 
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carboxyl groups of the peptide bond. This type of structure allows the stabilization of oligomers 
and aggregated proteins. On the contrary, natively folded proteins are mainly enriched in α-
helix structures, where the hydrogen bonds are between groups in the same strand. So, there is 
a correlation between the protein misfolding and the aggregation.  
 
Disease Clinical Features Protein 
AD Progressive dementia Ab and tau 
PD Movement disorders a-syn 
ALS Movement disorders SOD1 
TSEs Dementia, ataxia, psychiatric problems, insomnia Prion protein 
 
Table 1. List of some neurodegenerative disorders with their clinical features and proteins involved 
 
The conformational change and the onset of aggregation can be caused by many factors, such 
as mutations, environmental changes and chemical modifications. These factors reduce the 
conformational stability of the protein’s native form and lead to a shift of the equilibrium 
between the folded protein and the misfolded protein. In physiological conditions, the 
population of partially folded protein is refolded by molecular machineries such as molecular 
chaperones (i.e. heat-shock proteins, calnexin) and ubiquitin-protease pathway [9]. 
Under destabilizing conditions, general physiochemical features such as net charge, 
hydrophobicity and propensity to alpha and beta structure formation, affect the tendency of the 
unfolded or partially folded protein chain to aggregate and form amyloid fibrils [10]. All 
amyloid fibrils share the same main features, they are straight, unbranched, 6.12 nm wide and 
formed by a different number of elementary filaments (protofilaments) that are around 1.5-2.0 
nm in diameter, twisted around each other in a rope-like structure. These structural features are 
studied by transmission and cryo-electron microscopy, atomic force microscopy, NMR and X-
ray diffraction[11]. 
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1.1.1 Prion Diseases  
   
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are 
infective neurodegenerative disorders. The main hallmarks are spongiform lesions, glial 
activation and cell apoptosis, which lead to many different motor and cognitive symptoms. 
TSEs were defined as transmissible in early 1930s, by an experiment performed by Cuille and 
Chellè showing transmissibility of scrapie to goats [12]. Originally, this transmissibility 
hypothesis was considered as an unorthodox hypothesis. Afterward, Griffith speculated that a 
protein alone, without the presence of nucleic acids, could be the infectious moiety responsible 
for the disease [13]. Finally, in 1982 Stanely B. Prusiner proposed the prion hypothesis, stating 
that TSEs result from the conformational change of the native isoform of the prion protein 
(PrPC) into the scrapie isoform (PrPSc) [14].   
Prion diseases affect humans and a wide range of animal species. These disorders can arise 
sporadically, be inherited, or acquired through infection (Table 2). Animal TSEs include bovine 
spongiform encephalopathy (BSE) of cattle [15], scrapie of sheep [16], chronic wasting disease 
(CWD) of moose, elk and deer [17] and transmissible mink encephalopathy (TME) [18].  
Human prion diseases include fatal familial insomnia (FFI) [19], Gerstmann-Sträussler-
Scheinker syndrome (GSS) [20], Kuru syndrome [21] and Creutzfeldt-Jakob disease (CJD). 
CJD can be classified as:  
• sporadic (sCJD), the most common form, although very rare with an incidence of 0.6-
1.2 x 10-6 per year. The etiology is unknown, because no cause has been identified due 
to the failure of finding either an infectious or genetic etiology [22]. 
• familial (fCJD), which is the autosomal dominant form, caused by PRNP mutation.   
• iatrogenic (iCJD), which is attributed to tissue transplantation or to the use of 
neurosurgical instruments contaminated by individuals suffering of unrecognized TSEs. 
iCJD is considered one of the biggest catastrophes in the history of medicine.   
• variant (vCDJ), caused by the transmission of BSE prions to humans, as it occurred in 
the '90s [23].  
Kuru is another infectious prion diseases, like iatrogenic and variant CJD [21]. In this case, 
the transmission of prions was due to a ritualistic cannibalism of brain from relatives of New 
Guinea highlanders dying of Kuru [24]. 
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Specie Disease Sporadic Genetic Infectious 
Humans 
CJD 
GSS 
FFI 
vCJD 
Kuru 
• 
• 
• 
• 
• 
 
 
• 
• 
Cattle BSE • • • 
Sheep Scrapie • • • 
Cervids CWD • unknown • 
Mink TME • unknown unknown 
Feline FSE • unknown unknown 
 
Table 2. Human and animal prion diseases 
 
  
1.2 Prion Protein  
 
The term "prion", acronym of PRotinaceous Infective ONly particle, was coined by Stanley 
B. Prusiner [14]. The cellular prion protein (PrPC) is a ubiquitous protein expressed in the heart, 
immune system, skeletal muscle, pancreas, kidney, and both the central nervous system (CNS) 
and peripheral nervous system (PNS). In CNS and PNS it is localized in the membranes of 
neurons, astrocytes, oligodendrocytes, and Schwann cells.  
PrPC is a detergent-soluble, protease-sensitive, glycoprotein localized mainly in the 
extracellular membrane, attached throughout a glycosylphosphatidyl inositol (GPI) anchor [25].  
 
 
1.2.1 Biogenesis of PrPC 
 
The prion protein gene (PRNP in human or Prnp in other species) is highly conserved among 
different species. The open reading frame (ORF) encoded within a single exon [8, 26]. In 
humans, Syrian hamsters and opossums, the PrP gene comprises of two exons with the ORF 
localized in the exon 2, while in mice, sheep, cattle and rats the gene has 3 exons, with ORF 
present in the third exon. The other exons contain untranslated sequences including the 
promoter and termination sites. The PrP promoter contains multiple copies of GC rich repeats 
and is devoid of TATA box [27, 28]. In humans, PRNP is a single copy gene mapped in the 
short arm of chromosome 20, which corresponds to the homologous region of mouse 
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chromosome 2 where Prnp is located. PrP mRNA has been detected in a wide range of tissues 
and cell types, but the highest concentration is found in the brain, where in situ hybridization 
has demonstrated that the greatest abundance of mRNA is located in neurons [29, 30]. 
PrPC is highly expressed in the central (CNS) and peripheral nervous system (PNS), however, 
its content varies among different cell types, neurons and glial cells. The expression of mRNA 
and the protein is developmentally regulated, increasing postnatally with distinct time course 
for distinct regions. Indeed, the earliest expression is in the hippocampus, thalamus and 
hypothalamus.  
The pre-pro protein, as a typical cell-surface glycoprotein, is translocated to the endoplasmic 
reticulum (ER) and the presence of the 23 amino acids, that act as N-terminal peptide are then 
cleaved in the ER lumen. Here, the immature prion protein is susceptible to many post-
translational modifications, such as N-glycosylation at human residues N181 and N197, the 
formation of a disulfide bond at position C179 and C214 and cleavage of the C-terminal signal 
peptide and subsequent attachment of the glycosylphosphatidyl inositol (GPI) moiety at 
position 231 [31, 32]. In the co-translational translocation in the ER, PrP can be synthesized 
with three topologies in the ER. The secreted form of PrP that follows the traditional exocytic 
pathway to the cell surface, and two C- or N- terminal transmembrane forms, known as PrPCtm 
and PrPNtm, respectively, due to transmembrane insertion of the PrP hydrophobic domain 
(residues from 110 to 134) in the ER compartment [33, 34] (Figure 1). 
The GPI-anchored form is derived from the secreted form, which is fully translocated in the 
ER and is trafficked in the Golgi apparatus. In the Golgi, further processing of the N-linked 
oligosaccharides results in modified glycosylation to include complex-type sugar chains. N-
glycosylation of PrPC is variable, resulting in un-, mono- and diglycosylated forms, depending 
on the number of glycosylation sites occupied with the oligosaccharide chains [35]. The lipid 
rafts are membrane domains with a high level of mature PrPC. These membrane regions are 
detergent-resistant with many important cellular receptors and other GPI-anchored proteins 
[36]. Interestingly, the association of PrPC with lipid rafts seems to be required for its correct 
folding, as cholesterol depletion leads to its misfolding [37-39]. 
PrPC endocytosis occurs between the cell surface and endocytic compartments, in two 
possible ways: by clathrin-dependent pathway or mediated by caveolae -like domains.  
From the cell surface, PrPC can be endocytosed to internal endosomal compartments, delivered 
from early to late endosomes, and routed to lysosomes for degradation or recycled to the cell 
surface for ensuing cycles [40]. 
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Figure 1. Biogenesis of PrPC. PrPC (green coils) is synthesized, folded, and glycosylated in the endoplasmic 
reticulum (ER), where the glycosylphosphatidylinositol (GPI) anchor is added, before further modification in the 
Golgi complex. Mature PrPC translocates to the outer leaflet of the plasma membrane. Instead, PrPCtm and PrPNtm 
are unusual transmembrane forms, generated in the ER, which have their COOH or NH2 terminus in the ER 
lumen, respectively (modified from [41]). 
 
 
1.2.2 PrP structure  
 
The human PrP (HuPrP) gene encodes a 253 amino acids long pre-pro-protein that is 
subsequently processed as mentioned before. In the mature form, the first 22 residues are 
cleaved after translation, whereas the last 23 amino acid residues are cleaved prior to the 
addition of the GPI anchor to Ser231 [42, 43]. The mature human PrPC (HuPrP) is composed of 
209 residues with a molecular weight of 35-36 kDa. 
The majority of the structural data of PrPC were obtained by using the bacterially expressed 
recombinant PrP (recPrP) as a model. Although recPrP is not subjected to post-translational 
modifications, it is structurally equivalent to the physiological PrPC.  
Atomic structure obtained by NMR [44-46] and X-ray crystallography studies [47, 48] 
showed that the full length PrP has a very specific structure: a well-defined C-terminal part and 
a flexible N-terminal domain. The globular C-terminal domain consists of three a-helices (aa 
promised ER function. However, under chronic ER stress
conditions, the proteasome may become overwhelmed,
resulting in PrP accumulation in the cytosol. According to
the study of Rane et al. (417), even a modest increase in
PrP routing to pQC for prolonged periods of time causes
clinical and histological neurodegenerative changes rem-
iniscent, in some aspects, of those observed in prion
diseas s.
Although ER stress in prion diseases is well docu-
mented (217), he relevance or even the existenc of cy(PrP)
continues to be rather controversial (142, 152). Further-
more, the tr nsgenic mice with increas d PrP translocation
to the pQC pathway reported by Rane et al. (417) showed a
relatively mild neurodegenerative phenotype that resembles
only a subset of TSE pathology, and other cellular pathways
may also be contributing to prion-induced neurodegenera-
tion (472). A role for dysfunction of the ubiquitin-protea-
some system (UPS) in the pathogenesis of prion disease was
also suggested: neuronal propagation of prions in the pres-
ence of mild proteasome impairment triggered a neurotoxic
mechanism involving the intracellular formation of cytosolic
PrPSc aggresomes that, in turn, activated caspase-dependent
neuronal apoptosis. A similar effect was also se n in vivo in
brains of prion-infected mice (285). In a follow-up study, the
same group reported that disease-as ociated prion protein
specifically inhibited the proteolytic !-subunits of the 26S
proteas me. Upon chall nge with r combinant p ion and
other amyloidogenic proteins, only the prion protein in a
nonnative !-s eet co formation inhibited the 26S protea-
some at stoichiometric concentrations. Furthermore, there
FIG. 6. Toxicity mediated by abnormal topology or altered trafficking of PrPC. The normal cellular isoform of prion protein, PrPC (green coils),
is synthesized, folded, and glycosylated in the endoplasmic reticulum (ER), where its glycosyl phosphatidylinositol (GPI) anchor is added, before
further modification in the Golgi complex. Mature PrPC translocates to the outer leaflet of the plasma membrane. Instead, CtmPrP and NtmPrP are
unusual transmembrane forms, generated in the ER, which have their COOH or NH2 terminus in the ER lumen, respectively. It has been suggested
that misfolded and aberrantly processed PrP (cyPrP and CtmPrP, respectively) (orange coils), which would normally be degraded by the proteasomes
through the ER-associated degradation (ERAD) pathway, aggregate in the cytoplasm and cause cell death. Putative proteasomal inhibition or
malfunction during prion disease would contribute to this route of toxicity. Induction of ER stress by PrPSc may lead to translocation of nascent
PrPC molecules to the cytosol for proteasomal degradation as a way to alleviate the overloaded ER (pQC pathway). However, this mechanism of
defense turns negative under chronic ER stress conditions, overwhelming the proteasome and leading to the cytosolic accumulation of potentially
toxic PrP molecules (dashed lines).
1120 ADRIANO AGUZZI AND ANNA MARIA CALELLA
Physiol Rev • VOL 89 • OCTOBER 2009 • www.prv.org
Downloaded from www.physiology.org/journal/physrev by ${individualUser.givenNames} ${individualUser.surname} (147.122.129.034) on June 25, 2018.
Copyright © 2009 American Physiological Society. All rights reserved.
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144-154 a1, 173-194 a2 and 200-228 a3) and two antiparallel b-sheets (aa 128-131 b1 and 161-
164 b2) siding the first a-helix (Figure 2). A third β-sheet strand has been recently identified 
and named β0 [49, 50]. The α-helices have been shown to undergo a vast structural 
rearrangement into β-sheets in the pathogenic form. Indeed, in literature it is shown that, using 
a Fourier transform infrared spectroscopy (FTIR), the α-helix content of PrPC passes from 48% 
to ~24% in the pathogenic form, while the β-sheet content increases from 8%, in the 
physiological condition, to ~50% in PrPSc form. The a1 and a2 are the bulk of the structure and 
are linked by the disulfide bond between two cysteine residues, Cys179 and Cys 214 [51, 52]. 
The N-terminal (aa 23-124) is the unstructured domain and because of the flexibility of the 
chain this domain may be divided into four different consecutive domains: a first charge cluster 
or CC1, the octapeptide repeat (OR), a second charge cluster or CC2, and a hydrophobic 
domain (HD). The OR is a series of four or five octapeptide repeat of eight amino acids 
(PHGGGWGQ). The OR repetitions have a high affinity for copper ions (Cu2+) and a low 
affinity for other bivalent cations, for example Zn2+, Fe2+, Mn2+, Ni2+. Histidine and tryptophan 
residues were found to be essential for the coordination of copper and other bivalent metals, 
suggesting a role for PrPC in regulating the homeostasis of these cations [53]. CC1 and CC2 
(residues 23-27 and 95-110, respectively) seem to be involved in glycosaminoglycans (GAGs) 
[54, 55] and nucleic acids binding [56]. The CC1 region seems to be involved in recycling and 
internalizing PrPC from the cell surface [57]. However, mice lacking CC1 or CC2 domains did 
not show pathologies and are susceptible to prion infection [58]. The HD is believed to play a 
role in the PrPC function in concert with CC2. Indeed, ablation of CC2 in combination with a 
partial or complete deletion of HD causes severe pathologies in transgenic (Tg) mice, suffering 
from ataxia to cerebellar granule cell loss. While a partial deletion of HD is not toxic [59]. The 
HD contains the palindromic alanine-rich sequence AGAAAAGA, that lies within the so called 
“toxic peptide”. It has been shown that peptides corresponding to the palindrome are important 
in the conversion of PrPC to PrPSc; in fact, deletion of this region prevents conversion of PrP 
into the pathogenic form, and interferes with in vitro formation of protease-resistant PrP [52, 
60, 61]. 
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Figure 2. The structure of cellular prion protein. (A) Schematic illustration of primary PrPC structure, including 
post- translational modifications. (B) Secondary structure of PrPC. Histidine residues are highlighted in blue, 
copper ions in orange. The two cysteins of the disulfide bond are in light green, the two asparagines residues for 
N-glycosylation in dark green. 
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1.2.3 PrPC physiological functions and distribution 
 
Historically, the study of the PrPC started simultaneously with the discover of TSEs, since 
from the beginning it was clear that the cellular prion protein was the counterpart of the PrPSc. 
A fully understanding of its physiological role has been lacking for a long time. To look at the 
localization of PrPC is an important starting point to comprehend its biological functions. 
 
1.2.3.1 Expression and localization 
PrPC is a cell surface protein, expressed in different tissues and organs, but more present at 
the level of CNS and PNS. Even in the brain, the amount of PrPC varies from one region to 
another and from one cell to a different one, but in any case, the neurons are the cells where the 
PrPC is mainly expressed, indicating that this protein has a singular significance in these cells. 
The higher concentration of PrPC in the neuron is at the synapse level [62], but it is still under 
debate where exactly it is expressed, if at pre- or postsynaptic level or both [63].  
Based on these findings, many studies report that PrPC could have a crucial role in the 
synaptic maintenance, structure and function [64]. Likewise, appreciable amount of the cellular 
prion protein has been found in peripheral tissues, such as immune system, bone marrow and 
blood, indicating a different role also in these tissues [65].  
It is also important to understand when the protein is expressed. In literature, different works 
can be found that have been studying the PrPC presence in embryonic development. Prnp 
mRNA expression starts around the embryonic day 6.5 (E6.5) in extraembryonic tissues [66], 
E7.5 in the cardiac mesoderm [67] and E8 in the developing CNS [68, 69]. The involvement of 
PrPC in neuronal differentiation is confirmed by its high expression in all the regions where 
neurogenesis occurs, such as the ventricular zone, hippocampus, thalamus and hypothalamus, 
thus explaining the possible involvement in neuronal differentiation [70]. In human adult brain, 
PrPC is not only expressed in neurons, but it is consistently present in glia and endothelial cells 
of the blood-brain-barrier [71]. 
 
1.2.3.2 Knockout models 
In the beginning of 1990s, many groups created Prnp knockout mice to assess the primary 
PrPC function and to investigate whether the loss of this physiological function could bring to 
neurodegeneration in prion diseases.  
In 1992, Büeler and his colleagues produced the first Prnp null mouse strain (Prnp-/-), named 
Zurich I (ZrchI), mixing C57BL/6J x 129/Sv(ev) background, by replacing codon 4–187 with a 
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neomycin phosphotransferase expression (neo) cassette [72]. The second line of Prnp null 
mouse, the Npu or Edimburgh (Edbg) was generated by interruption of the Prnp ORF at 
position 93 and introduction of a neo cassette [66, 73]. These two lines of mice, in a first round 
of characterization did not present any developmental alterations, suggesting that normal PrPC 
is not necessary for normal physiological functions in the mice strains, but they were resistant 
to prion infection, demonstrating that PrPC is fundamental for developing TSEs [73]. 
In contrast with these first findings, Nagasaki (Ngsk) PrPC-deficient mice, in which the entire 
Prnp gene was removed, develop ataxia and Purkinje cells degeneration. This phenotype, 
which is completely abolished by the reintroduction of PrPC, was imputed to the loss of the 
protein [74, 75]. The same phenotype was observed in other two Prnp null mice strains, Rcm0 
[76] and Zurich II [77]. Later it was demonstrated by several groups that the presence of this 
phenotype was due to the upregulation of Doppel (Dpl), a protein expressed in testes and 
encoded by the gene Prnd, located 16 kb downstream Prnp, which generally is not expressed in 
the brain [76, 78]. Thus, showing that only the ectopic expression of Dpl, rather than the 
absence of PrPC, was the cause of the neurodegeneration observed, precludes an association of 
these differences with the lack of PrPC expression.  
Although ZrchI and Edbg mice did not present any obvious physiological abnormalities, 
these mice lines provided a platform for experiments aimed at gaining further insight on the 
role of PrPC in the context of behaviour, sleep-wakefulness cycle, memory, synaptic activity 
and neuronal excitability.  
 
1.2.3.3 Role of PrPC at the synaptic level 
As mentioned above, the cellular prion protein in highly expressed in both neurons and glial 
cells. In neurons, PrPC is mainly localized in pre- and post- synaptic compartments. 
Immunocytochemical studies showed that PrPC is enriched along axons and in pre- and 
postsynaptic terminals [79] and that it undergoes anterograde and retrograde axonal transport. 
Recently, it has been shown that sialic acid within GPI-anchor is important for targeting PrPC to 
synapses [80]. These observations suggest a role of PrP in preserving normal synaptic structure 
and function by regulating synaptic transmission plasticity; indeed, synaptic dysfunction and 
synaptic loss are early events in prion diseases. 
The long-term potentiation (LTP), that is correlated with synaptic plasticity and so with 
learning and memory formation, is affected by the presence of PrPC. Indeed, some studies 
report deficiencies in spatial learning and memory in PrPC-deficient mice. Interestingly, these 
results are in contrast with a work carried out in Prnp ZH1/ZH1 mice that did not show 
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memory impairment. Thus, the role of the cellular prion protein in memory and learning has 
not been established yet [81]. 
Another important activity that has been related to the synaptic PrPC is the sleep homeostasis 
and the sleep continuity. A study from 1996 conducted by Manson’s group revealed that 
PrnpZH1/ZH1 and co-isogenic PrnpEdbg/Edbg mice display altered circadian rhythms, increased 
sleep fragmentation, and increased slow wave activity (SWA) following sleep deprivation [82]. 
These findings explain the typical symptoms that occur during different prion diseases such as 
the sporadic [83] and fatal familial insomnia [84], where this phenotype is completely rescued 
by the reintroduction of PrPC expression [85]. However, the molecular mechanism of sleep 
regulation activity of PrPC is still not understood; even if a recent study claims that the calcium-
dependent hyperpolarization is critical to sleep duration, and that sleep deterioration is 
associated with impairment of calcium-dependent potassium channels, voltage-gated calcium 
channel (VGCC) and N-methyl-D-aspartate (NMDA) glutamate receptors, which are activated 
by S-nitrosylation mediated by PrPC and copper ions [50, 86]. 
 
1.2.3.4 Interaction of PrPC with other proteins 
The cellular prion protein interacts with several different proteins, that have been identified 
and analyzed to better understand the PrPC functions. 
STI1 is a heat shock protein characterized in a macromolecular complex with Hsp70 and 
Hsp90 chaperone family protein, that are localized in the cytoplasm and a small part at the cell 
membrane, where it seems to bind PrPC [87]. The interaction between STI1 and PrPC induces 
neuroprotective signals that rescue cells from apoptosis via cAMP/protein kinase A and the Erk 
signaling pathways [88]. 
LRP is another cell surface PrPC ligand. This protein mediates the internalization of the 
cellular prion protein and directs the complex through clathrin coated pits. LRP was suggested 
to act as a putative PrPC receptor because it was shown to co-localize with PrPC on the surface 
of both N2a and baby hamster kidney cells [89]. 
PrPC has also been identified in a complex with NCAM, which is the neuronal cell adhesion 
molecule. This complex mediates a signaling cascade involving the p59fyn, inducing the 
neurite outgrowth and neuronal survival [90, 91]. 
 
The PrPC is involved in many other physiological activities, such as the regulation of copper 
concentration at the synaptic level [92], protection against oxidative stress [59, 93], secretion of 
exosomes [94], and many others that are not cited here (Table 3). So, it seems that the cellular 
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prion protein is fundamental for myriads of functions, but at the same time appears to be 
dispensable for the development. Achieving a complete picture of PrPC biological functions is 
crucial for the development of drugs able to restore PrPC activity in prion diseases and other 
pathological settings. 
 
Role of PrPC Phenotype of Prnp-/- model system 
Synaptic transmission and plasticity 
-Reduced long-term potentiation 
-Reduced excitatory and inhibitory synaptic      
transmission 
Memory formation 
-Reduced spatial learning and memory 
-Reduced avoidance learning and memory 
Stabilization of sleep and circadian rhythm 
-Altered circadian rhythm, increased sleep 
fragmentation, increased SWA after sleep deprivation 
Neuronal excitability 
-Reduced Kv4.2 currents  
-Reduced sAHP and calcium-activated potassium 
currents 
Calcium homeostasis 
-Reduced VGCC currents  
-Increased calcium buffering  
Glutamate receptor function 
-Upregulation of Kainate receptor subunits  
-Increased NMDA currents, nociception and 
depressive-like behavior 
Neurite outgrowth 
-Reduced neurite outgrowth in vitro  
-Delayed development of cerebellar circuitry  
Toxicity elicited by oligomeric species 
-Protected from LTP reduction induced by toxic Aβ 
species 
Neuroprotection -Larger lesions in model of acute cerebral ischemia 
Copper, zinc, iron, and lactate metabolism 
-Reduced zinc content in primary neurons 
-Increased lactate-uptake in cultured astrocytes 
Peripheral myelin maintenance -Age-dependent demyelinating neuropathy 
 
Table 3. Physiological roles of cellular prion protein [81]. 
 
 
1.3 PrPSc: the infectious agent 
 
PrPSc is the alternative and misfolded isoform of the PrPC. This abnormal conformation of the 
prion protein accumulates and forms deposits around neurons. The common feature of all prion 
diseases is the presence of PrPSc aggregates. For a long period, it has been thought that the 
scrapie prion protein was the only misfolded protein that could be transmitted, but in the last 
decades many different studies showed the transmission of the other misfolded proteins, such 
as amyloid Ab [95], tau [96] and a-synuclein [97].  
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The conversion process is associated with conformational changes of the secondary structure 
from α-helices to β-sheets. Indeed, when the conformational change occurs, PrPC switches from 
a structure composed by 45% α-helices and a few β-sheets (~3%), to a form with 30% α-helices 
and 45% β-sheets [98]. With this composition, the PrPSc aggregates are partially resistant to 
protease K digestion, in fact, limited protease digestion of PrPSc produces a smaller, protease-
resistant molecule of approximately 142 amino acids, referred to as PrP 27–30 (PrPres) while 
PrPC gets entirely degraded (Figure 3). Protease K is the common method to distinguish PrPSc 
from PrPC, by means of Western blot technique and although resistance to limited proteolysis 
has proved to be a convenient tool for detecting PrPSc, not all PrPSc molecules are resistant to 
protease digestion [98, 99]. These protease-sensitive PrPSc forms are denoted sPrPSc [100, 101]. 
Furthermore, PrPSc from different species or prion strains may show different degrees of 
protease resistance.  
 
 
Figure 3. Detection of PrPSc in prion infected and uninfected cells. Western blot. Lysates of N2a or prion-
infected N2a cells (ScN2a) were treated with proteinase K and analysed by SDS-PAGE and Western blotting 
with anti-PrP antibody [102]. 
 
1.3.1 Prion strains and species barrier  
 
The prion strain phenomenon is another unique feature of TSEs respect to the other 
neurodegenerative disorders. It has been observed that animals affected by prion diseases can 
develop different pathologies and that the clinical and biochemical outcomes could be 
maintained through several passages in rodent’s models of prion diseases. Similar to other 
infectious agents, these variants have been termed “strains”. Due to the fact that prions are 
88
potential therapeutic values; and (iv) the determination of biological
markers of the infection with potential diagnostic and physiological interest.
Cellular cultures supporting TSE agent replication
The most straightforward approach to propagate prions ex vivo is to put
infectious fractions in contact with cell culture and to check for the
‘replication’ of the agent. Different infectious fractions have been used,
the simplest being represented by brain homogenates. In some instances,
partially purified preparations (scrapie-associated fibrils, SAFs) have
also been used3, but it is not clear if this results in a higher effectiveness
of transmission. As for animal assays, pretreatment of the infectious
fraction for 30 min at 80°C followed by sonication has been used to
reduce the risk of transmission of conventional viral and bacterial
agents. This method also reduces the toxicity of the fractions on cell
cultures (personal observation). Following the ‘inoculation’ of the
culture, the cells are generally washed extensively and passaged several
times. Importantly, before the discovery of PrPSc, the success of prion
transmission to cell culture was only assessed by the presence of
infectivity. Animals were inoculated with cell extracts after sufficient
passages in vit o o rule out the detection of the remaining infectivity
f om the inoculum.
With the demonstration of the close association between PrPSc
production and prion propagation, the detection of this isoform became
a useful marker in cell culture. It was then demonstrated4, using
metabolic labelling, that infected cultures could generate new molecules
Prions for physicians
British Medical Bulletin 2003;66
Fig. 1 Different ways to detect PrPSc in prion-infected cells. (A) Western blot. Lysates of N2a or prion-infected N2a cells
(ScN2a) were treated with proteinase K and analysed by SDS-PAGE and Western blotting with anti-PrP antibodies.  (B)
Slot blot. Cell lysates of N2a and ScN2a cells were filtered through nitrocellulose membranes with a slot blot device
and PrPSc detected as described in (C). (C) Cell blot. N2a or ScN2a grown on cover-slips were directly transferred onto
a nitrocellulose membrane and PrPSc was revealed, after proteinase K digestion, with anti PrP antibodies by Western
blotting.
Downloaded from https://academic.oup.com/bmb/article-abstract/66/1/87/284862
by gues
on 01 July 2018
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composed only of proteins and replicate using the PrPC substrate present in the host, differences 
in prion strains cannot be attributed to genetic variability, which accounts for the existence of 
viral strains. Rather, prion strains arise from conformational variability, because PrP can 
assume several different, self-propagating conformations, each of which enciphers a distinct 
prion strain. However, currently it is widely accepted that the main differences between prion 
strains arise from alternative conformations of PrPSc that can be stably and faithfully 
propagated [103, 104]. The differences in these conformations result in differences in resistance 
to PK digestion and electrophoretic mobility after PK digestion [105-107], varying 
glycosylation patterns [108], sedimentation velocities and resistance to urea and guanidinium 
hydrochloride denaturation [109]. Also, recent studies with synthetic prions support this theory 
[99, 110].  
The transmissibility of PrPSc between mammalian species is another really important feature 
of this infectious agent. But, the transmission is limited by the so called “species barrier” [111]. 
The phenomenon refers to the difficulty to transmit the infectious prion agent from one specie 
to another, and can be characterized by extended incubation times, but if prions are then re-
isolated from the recipient host and re-transmitted to another host of the recipient species, the 
incubation period decreases and the prions are “adapted” [112]. (One of the causes for the 
species barrier are the sequences of the potential prion proteins of the two species.) In 1939, the 
first experimental transmission of TSE between species was carried out with scrapie between 
sheep and goats, showing 100% susceptibility, demonstrating that goats are highly susceptible. 
Then, further experiments were performed with other species to test their susceptibility to 
TSEs. The results demonstrated that some animals have a very low susceptibility to prion 
infections (i.e. rabbits and guinea pigs) [113], in contrast to other species, which are unusually 
susceptible (i.e. hamsters and bank voles) [114]. 
In the last decades, this topic has been a subject of great interest because of the epidemic of 
BSE in cattle. BSE is the only example of TSE agent transmission to humans from another 
specie. It is thought that the source of BSE infection in the United Kingdom was sheep scrapie 
contamination resulting from the practice of feeding cattle with rendered sources of mammalian 
ruminant protein, such as meat and bone meal, derived from the offal of cattle, sheep, and pigs 
as a high-protein nutritional additive. Overall, more than a million cattle are thought to have 
been infected and after some years of this epidemic a new form of CJD, called variant CJD 
(vCJD) emerged [106]. Many studies demonstrated the hypothesis that vCJD emanated from 
BSE in cattle, but just a small portion considering the 60 million people and all visitors present 
in Britain during the peak of BSE epidemic. Indeed, just around 170 cases of vCJD have been 
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documented since 1996 and now the epidemic has stopped, thus demonstrating the poor 
transmissibility of BSE to humans by ingestion [115]. Nowadays, the scientific community is 
alerted by another TSE epidemic, the CWD in cervids, that is continuously spreading not only 
in the North America [116, 117] and Canada [118], where the cervids meat is commonly used 
as food [119], but even in Europe [120] and a single case in South Korea [121]. Several 
laboratories are now studying whether the species barrier exists in this case, and recently Race 
showed that the cynomolgous macaques are immune to intracerebral and oral CWD infection 
[122]. 
 
 
1.3.2 Conformational conversion of PrPC to PrPSc 
 
According to the protein-only hypothesis, the central molecular event in the replication of 
prions is the self-propagating conversion of PrPC to PrPSc, but unfortunately the mechanism 
remains subject of debate. It is thought that PrPC binds PrPSc forming an intermediate complex 
before forming new PrPSc. 
Once prions enter an organism, an exponential replication process begins generating more 
and more PrPSc particles. When a critical threshold level of particles is reached, animals show 
clinical symptoms of neurologic dysfunction and then die [123]. The time between inoculation 
and the appearance of clinical signs is denominated incubation time.  
There are two models to explain the conformational conversion of PrPC to PrPSc, the 
"refolding" and the "seeding" models. 
• In the "refolding" model or template assistance model, PrPSc has an instructive role 
towards PrPC. There is an interaction between the exogenous PrPSc and the endogenous 
PrPC and the products of this reaction are new molecules of endogenous PrPSc, which 
can transform other endogenous cellular prions in the scrapie isoform with a 
consequential propagation and aggregation. A high energy barrier can prevent the 
spontaneous conversion (Figure 4) [123]. This model is supported by spectroscopy at 
high pressure [124] and changes between hydrogen-deuterium studies [125]. 
• The “seeding” model, also known as seeded nucleation model, suggests that PrPSc can 
be physiologically present in the organism. The two forms are in a reversible 
equilibrium, but the PrPC isoform is thermodynamically favored. Only when several 
molecules of PrPSc are aggregated (into oligomeric or fibril-like seeds), the replication 
can start. In this case, the seed recruits other monomeric PrPSc molecules and stabilizes 
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them, thus creating the amyloid. The fragmentation of aggregates increases the number 
of nuclei, which can recruit further PrPSc with an acceleration of the process, thus 
resulting in apparent replication of the agent [41]. 
 
 
Figure 4. The protein-only hypothesis and the two models for the conformational conversion of PrPC into 
PrPSc. (a) The refolding model. (b) The seeding model. [126]. 
 
These models do not exclude each other, rather they are relevant to any types of diseases: 
• in the genetic type, the PRNP mutation leads PrPC to change spontaneously its tertiary 
conformation or the mutation can decrease the energy barrier between PrPC and PrPSc, 
thus facilitating and accelerating PrPSc aggregation; 
• in the infective type, the ingestion of PrPSc can directly convert endogenous molecules 
of PrPC; 
• in the sporadic form, the unknown biochemical modifications can change tertiary 
structure and promote the conversion in PrPSc. 
PrPC is generally localized in lipid rafts onto the plasmatic membrane. There are two 
proposed conversion sites of PrPC into PrPSc: the cell surface or the endosomes. In ScN2a cells, 
particularly, PrPSc aggregates in endosomes and lysosomes, while a small amount is converted 
on the cell surface [127]. The PrPSc that is formed in the endosomes aggregates and causes the 
impairment of the proteasome, while the cellular surface PrPSc creates extracellular oligomers, 
fibrils and then amyloid plaques. Both, the extracellular and the intracellular PrPSc promote 
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tain informational nucleic acids — in that they are
self-perpetuating and heritable7.
Eighteen years after Stanley Prusiner formulated
his PRION-ONLY HYPOTHESIS (FIG. 2) — for which he was
awarded the Nobel Prize in 1997 — there is still uncer-
tainty as to whether these two definitions coincide in
the case of mammalian prions, as it has not yet been
unequivocally established that the disease-associated
protein isolated by Prusiner and termed PRPSC represents
the infectious agent. Another problem is that, although
all AMYLOID PROTEINS and their precursors would fit the
second definition, these proteins do not seem to be
transmissible or infectious in vivo or in cell culture.
Although several yeast proteins have been shown to
fulfil both of these criteria (BOX 1), no such successes
have been reported for mammalian prions.
What is a prion?
The normal mammalian prion protein is known as PRPC.
In vitro conversion of this protein can yield a moiety
that has many of the physico-chemical properties that
are characteristic of PrPSc, the disease-associated prion
protein. These include aggregation into higher-order
quasi-crystalline complexes that are birefringent when
observed under polarized light (especially when stained
with amyloid dyes such as Congo red), formation of fib-
rils that are identifiable by electron microscopy and par-
tial resistance to proteolytic enzymes, as identified by
digestion with proteinase K8–10.
The crucial element that is common to the two defi-
nitions mentioned above, and that is absolutely required
for the classification of a protein as a prion, is transmis-
sibility. None of the experimental procedures reported
so far has unambiguously accomplished transformation
of the cellular prion protein PrPC into a transmissible
agent. Speculations abound as to why this has not been
possible: the requirement for additional cellular factors
distinct from PrPC, for example, has been invoked on the
basis of genetic evidence11, but has never been proved.
Universal consensus about the nature of the agent will
predictably be reached only once a synthetic reconstitu-
tion has been done from non-infectious material.
How the prion damages its host
Notwithstanding all the unresolved problems, certain
properties of the infectious agent can be studied.
Perhaps the most obvious question is this: how do pri-
ons damage the central nervous system, which is the
only compartment of the body that undergoes
histopathologically (FIG. 3) and clinically detectable
degeneration in prion diseases?
Cellular models of prion disease might be useful to
address this question, although prions replicate ineffi-
ciently in most established cell lines. Many studies have
been done using a synthetic peptide from the central
region of the PrPC molecule, which spontaneously
assembles into amyloid-like structures. In vitro, this
peptide can elicit reactions that resemble those seen in
brain cells during the late stages of prion disease. These
include activation of microglial cells, stimulation of the
production of intermediate filaments by astrocytes,
and even the death of neurons, all of which seem to
depend on the presence of the normal prion protein in
target cells12,13. But all of these studies suffer from a
fundamental problem. It is not clear whether the phe-
nomenon observed in conjunction with exposure of
cells to this small, amyloidogenic peptide bear much
relevance to what is happening in vivo during prion
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Figure 2 | The ‘protein-only’ hypothesis and two popular models for the
conformational conversion of PrPC into PrPSc. a | The ‘refolding’ or template-assistance
model postulates an interaction between exogenously introduced PrPSc and endogenous PrPC,
which is induced to transform itself into further PrPSc. A high-energy barrier might prevent
spontaneous conversion of PrPC into PrPSc. b | The ‘seeding’ or nucleation–polymerization
l proposes that PrPC and PrPSc are in a reversible thermodyn mic equilibrium. Only if
several monomeric PrPSc molecules are mounted into a highly ordered seed can further
monomeric PrPSc be recruited and eventually aggregate to amyloid. Within such a crystal-like
seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the number of
nuclei, which can recruit further PrPSc and thus results in apparent replication of the agent. In
sporadic prion disease, fluctuations in local PrPC concentration might — exceedingly rarely —
trigger spontaneous seeding and self-propagating prion replication.
Figure 1 | Confirmed cases of BSE plotted by month and year of onset. Data valid to end
of January 2000 (produced in June 2000). The good ews is that the epizootic has b en
receding since 1992. The not-so-good news is that, despite several predictions, the incidence
has not reached zero, and seems to be levelling off asymptotically at a low, but measurable,
height. (Source: British Ministry of Agriculture, Fisheries and Food.)
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neurotoxicity [128, 129]. 
The literature points to the presence of cellular co-factors in prion replication. These factors 
are present only in mammals, not in bacteria, yeast or flies. They are mainly referred to as 
"protein X", but there is no evidence for the nature of this factor. Many in vitro studies suggest 
that different molecules, such as RNA, may be involved in this mechanism [36]. Five scenarios 
are proposed to explain the cofactor rules in prion conversion: 
1. The cofactors bind the infective agent and promote PrPSc aggregation. 
2. The cofactors act as catalysts and favor PrPC to initiate PrPSc conversion. 
3. The cofactors only stabilize the PrPSc conformation. 
4. The cofactors promote the fragmentation of PrPSc in small seeds, which allows for 
       prion replication. 
5. The cofactors bind PrPSc, decreasing its clearance in vitro. 
Therapies that target these factors could be effective in blocking prion replication [1]. 
It is important to keep in mind that these co-factors can help the replication, but they are not 
crucial for the prion replication. Indeed, the final proofs for the “protein-only hypothesis” have 
been provided by: 
- the first PrP knockout transgenic mice models [72]. These mice develop normally in the 
absence of PrP and are resistant to prion infection [130]. 
- techniques able to mimic the prion conversion and replication in vitro: the protein 
misfolding amplification technique (PMCA) [131], amyloid seeding assay (ASA) [132] and 
Real Time Quaking Induced Conversion (RTQuIC) [133], that will be dealt with here. 
 
 
1.3.3 Prion infectivity and neuroinvasion in humans  
 
As mentioned above, the media and the scientists have devoted particular attention to the 
infectious TSEs, because of the epidemic of BSE in the United Kingdom and its capability to 
cross the species barrier and infect humans, but unfortunately the route of infection is still 
poorly known.  
In transmission experiments, there are different possible routes of infections, due to different 
routes of prion inoculation: 
• Intracerebrally, in which prions replicate directly in the brain, where PrPC expression 
level is higher [134]. However, this is not what happens in nature. 
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• Intraocularly, that can occur both in animal experiments [135], either in iCJD patients 
[136], these cases were caused by the transplant of prion-contaminated corneal grafts. 
• Intravenously [137], with less efficiency than intracerebral injection [138]. Accidental 
prion transmission via this pathway was long underestimated due to the low presence 
of prions in human blood. However, reports exist of vCJD cases due to blood 
transfusion [139]. 
• Intraperitoneally [137] 
In acquired prion diseases, Kuru, vCJD, BSE, TME, the most common route of infection is 
due to oral exposure of PrPSc contaminated food (Table 4). 
After an oral infection, prions can be found in Peyer’s patches in the gut, then the prion 
propagation continues into splenic lymphoid tissue and/or in gut-associated lymphoid tissue 
(GALT, which includes tonsils), resulting in prion transport by splenic innervation to the 
brainstem and spinal cord [140, 141]. 
The route of infection is defined by three phases: 
1. In the first phase, after ingestion, there is the PrPSc invasion of the gut-associated lymphoid 
tissues (GALT). The incorporation of PrPSc into the intestine is mediated by a Fc receptor 
(nFcR), which contributes to the uptake of maternal antibodies into the intestine [142]. Another 
study demonstrated that the iron binding protein ferritin forms a complex with a fragment PrPSc 
to enhance the transport of PrPSc in an intestinal endothelial cell model, suggesting a role for 
ferritin in transport of infected prion protein across the intestine [143]. 
2. After incubation in lymphoid tissues such as GALT and spleen, the PrPSc spreads to the 
CNS via the enteric nervous system. This invasion occurs in the retrograde direction along 
efferent fibers of both sympathetic and parasympathetic nerves. 
3. The final phase is the infection of the spinal cord and brain leading to a characteristic 
spongiform degeneration and astroglial activation. 
The natural horizontal transmission is another way of prion infection, typical for some TSEs 
such as scrapie or CWDs. This transmission is maintained within their animal population 
through their persistence in the environment. It was believed that this transmission route was 
caused by prion excretion because of the important role played by lymphoid tissues in prion 
dissemination and pathogenesis [144]. Prions should spread from lymphoid tissue to other 
tissues and be secreted in placenta, saliva, urine, and feces into the environment [145, 146]. But 
it is also known that, the lymphoid tissue has a minor role in the pathogenesis of BSE in cattle 
and BSE prions are mostly confined to the central nervous system [147, 148]. While, BSE 
prions in sheep accumulate mainly in the lymphoid organs [149]. It is not known why some 
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prion strains are capable of such dissemination outside the central nervous system while others 
remain in the brain even if elicited by oral challenge but it seems to be a consequence of 
complex prion strain–host interactions [150]. 
 
Infection route Source of prions Prion diseases Several animal models 
Intracerebral 
Experimental 
Prion-contaminated 
neurosurgery material, 
electrode probes, and dura 
mater grafts 
Several TSEs 
iCJD 
Several animal models 
Human 
Oral 
Prion-contaminated food 
products 
Kuru, vCJD, BSE, TME Human, cattle, mink 
Ocular 
Experimental 
Prion-contaminated corneal 
grafts 
Several TSEs 
iCJD 
Several animal models 
Human 
Intravenous 
Experimental 
Prion-contaminated blood 
products 
Several TSEs 
vCJD 
Several animal models 
Human 
Horizontal 
transmission 
Environmental 
contamination Scrapie, CWD 
Sheep, goat, cervid 
species 
 
Table 4. Summary of Prion Infection Routes and Corresponding Prion Diseases [150] 
 
 
1.4 Diagnosis 
 
As mentioned above, prion diseases are illnesses that affect the CNS. For all the 
neurodegenerative pathologies, the diagnosis is based mainly on clinical examination and the 
diseases are considered possible depending whether the clinical symptoms fit the standard 
guidelines [151], because the most reliable technique is the immunohistochemical detection of 
brain tissue. This is due to the fact that each neurodegenerative disease has a very specific 
neuropathological feature. For example, an AD brain contains amyloid plaques, neurofibrillary 
tangles, dystrophic neurites containing hyperphosphorylated tau, that are accompanied by 
astrogliosis and microglial cell activation [152]; PD is characterized by neuronal inclusions 
composed of α-synuclein, called Lewy bodies, that lead to a loss of dopaminergic neurons of 
the substantia nigra that project to the putamen [153]; and CJDs are associated with presence of 
prion deposits, spongiform degeneration and a strong astrogliosis [154].  
 
 
 
 
__________________________________________________________________________ 
 
36 
1.4.1 Diagnostic Tests 
 
The definitive diagnosis can only be made post-mortem by brain histological analysis or by 
brain biopsy. Although brain biopsy has been used to establish a definitive diagnosis, it is 
strongly discouraged because it is invasive, costly and can lead to brain injury and other side 
effects. Recently, some less invasive biopsy options were evaluated, such as the use of 
olfactory mucosa and skeletal muscle, but in the end, they were not validated or adopted [155]. 
It is also known that PrPSc of vCJD, but not from sCJD patients, could be detected in tonsils 
[156]. The main technique used to detect the presence of prions in the tissue taken from the 
brain biopsy is PK treatment followed by a Western blot analysis. 
The electroencephalography (EEG) has been used to diagnose CJDs since 1954. Periodic 
sharp wave complexes are the hallmark EEG finding in patients with CJD and are thus very 
helpful to substantiate the clinical diagnosis of suspected CJD. The EEG is useful to detect 
patients with sCJD, because very specific bilateral alpha activity with irregular theta, delta, and 
intermittent high amplitude rhythmic delta waves were found during the early stages of sCJD 
[157]. But the pattern just mentioned could change for different sCJD subtypes and is also 
present only in the sporadic form of CJD, for instance, in vCJD patients the EEG does not 
present the specific wave. In addition, this technique has a low sensitivity causing false 
positives [158] and can bring to a diagnosis of AD [159, 160]. 
Another non-invasive technique used to diagnose prion diseases in humans is the magnetic 
resonance imaging (MRI). Despite the increasing use of MRI, it is generally accepted that 
imaging technologies are used mainly to exclude other causes of pathology [161], because also 
in this case characteristic changes in MRI features are different for each prion diseases. Indeed, 
MRI is useful to discriminate between vCJD and sCJD, changes in the nucleus caudatus are 
usually seen in sCJD, while most changes are observed in the posterior thalamus [162] and the 
bilateral pulvinar in vCJD [163]. It is important also to specify that in sCJD changes are 
observed mainly using diffusion-weighted images (DWI), while in vCJD using fluid-attenuated 
inversion recovery (FLAIR) [164], where the sensitivity and specificity based on objective 
criteria are at approximately 80% [165]. The limitation of MRI on CJD diagnosis is associated 
with the interpretation, skill, and expertise of clinicians. The MRI features associated with CJD, 
especially in its early stages, may not be detected by a clinician or a radiologist as opposed to 
an experienced neuro-radiologist or a prion disease specialist. Thus, diagnoses may be missed, 
delaying further investigation. This suggests that even if an initial MRI is regarded as normal, a 
specialized review should still be carefully considered. 
 
__________________________________________________________________________ 
 
37 
An increase of many neuronal and astroglial proteins during the TSEs have been identified 
[166]. For example, in the cerebral spinal fluid (CSF) of sCJD patients the level of the proteins 
S-100 [167] and neuron-specific isoenzyme [168] are markedly spread. The 14-3-3 protein is 
mostly used as a neuronal death marker to help with the diagnosis of sCJD and fCJD [169], but 
it is absent in the CSF of patients with GSS and FFI. As the 14-3-3 protein might be elevated in 
the cerebrospinal fluid of patients with other neurological illnesses, the usefulness of this test 
depends on the exclusion of other pathologies [151]. 
It is evident that there is still not an efficient and completely reliable diagnostic test for TSEs, 
so the clinicians make the diagnosis combing the use of these techniques, and the recognition of 
the specific clinical symptoms. The sCJD patients are mainly affected by a combination of 
rapidly progressive multifocal dementia with pyramidal and extrapyramidal signs, and visual or 
cerebellar signs [161]. vCJD appears initially as a progressive neuropsychiatric disorder 
characterized by symptoms of anxiety, depression, apathy, withdrawal and delusions [170]. 
While GSS is characterized by dementia, Parkinsonian symptoms and a relatively long duration 
(5–8 years) [171]. Symptomatically, the GSS is similar to AD, but in GSS ataxia and seizures 
are really common. In all the inherited prion diseases, the diagnosis is established by genetic 
screening for prion mutations. 
 
 
1.4.2 The need of a pre-symptomatic diagnosis 
 
Pre-symptomatic detection of CDJs in live patients is so far, not possible, but it is extremely 
important for different reasons: 
• To develop an efficient anti-prion therapy. It is known that when people start to have 
symptoms in all the neurodegenerative diseases, the brain alterations and impairments 
are extensive and irreversible. This is also evident from the animal models data, several 
compounds can delay the onset of the disease and increase the survival time, but none 
of them has shown a significant effect when the treatment was started at the 
symptomatic stage [126]. 
• To assess the possibility of people incubating the disease. This necessary started with 
the BSE epidemic and then with the appearance of vCJD. In order to completely stop 
the epidemic, it could be important to have tests able to detect bovine that are 
incubating the disease at the symptomatic stage, because it is possible that infected 
animals that do not show the clinical signs of BSE and that give a negative result using 
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the available biochemical tests are still entering the food chain and presenting a serious 
risk to human health [172]. Also, the iCJD transmission is born by corneal transplants, 
implantation of electrodes in the brain, dura mater grafts, contaminated surgical 
instruments and treatment with human growth hormone derived from cadaveric 
pituitaries of people with sCJD [173]. 
 
 
1.4.3 New approaches: PrPSc amplification 
 
Recently, two techniques able to mimic the prion conversion in vitro and to amplify the PrPSc 
have been developed: the protein misfolding cyclic amplification (PMCA) and the Real-Time 
Quacking-Induced Conversion (RT-QuIC). These techniques can detect and promote the 
amplification of a very low amount of PrPSc present in a several types of samples, such as brain 
homogenates, blood, urine and olfactory mucosa. 
 
1.4.3.1 PMCA  
In 2001 Soborio et al. developed a system able to mimic in vitro the PrPSc conversion process 
that takes place in vivo, and that amplifies in an exponential fashion minute quantities of PrPSc 
present in a sample, based on the nucleation/polymerization model [131]. Basically, it consists 
of the incubation of a large excess of PrPC from a healthy brain homogenate (usually 10-10 
dilution factor) with PrPSc derived from TSEs infected sample. In each cycle, there are two 
different phases present. In the first one, the sample that contains a low amount of PrPSc and an 
excess of PrPC is incubated to promote growing of PrPSc aggregates. While during the second 
phase, the sample is sonicated in order to break the PrPSc polymers, increasing the number of 
nuclei (or seeds) (Figure 5). It follows that, as it happens for the DNA in PCR, if the cycles are 
more than one, the number of seeds increases in an exponential fashion. So, one round of 144 
PMCA cycles leads to a 6000-fold increase of sensitivity of detection, whereas 2 and 7 rounds 
of successive PMCA result in 10 million and 3 billion folds amplification [174]. It has been 
shown that PMCA is able to detect and amplify a single molecule of PrPSc. The presence of 
newly generated PrPSc has been confirmed by different biochemical assay, such as the 
resistance to PK digestion or insolubility in non-ionic detergents. 
This assay was developed using animal models of TSEs (infected mice [175], hamster [151], 
cattle[176] and cervids [177]).  
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But recently, PMCA has been studied as a possible diagnostic tool to detect prions in many 
different human tissues, such as blood in patients with vCJD [178], the olfactory mucosa (OM) 
of FFI individuals [179], urine in vCJD [180] and also plasma in symptomatic and pre-
symptomatic vCJD patients [181]. In all these tissues and prion diseases, the efficiency of 
PMCA to detect PrPSc is extremely high. So, it is probable that soon this technique will be 
introduced as a usual diagnostic test for human and animal TSEs. 
 
 
Figure 5.  PMCA (A) Representation of PMCA procedure. [131] (B) Amplification of PrPSc detected by Western 
blot [182]. 
 
 
1.4.3.2 RT-QuIC  
The RT-QuIC assay was illustrated by Atarshi and collegues in 2008 [183], then it was 
applied for human [184] and animal [185] diagnostic purpose. In this assay, the test samples, 
which can or cannot contain prions, are added and mixed to a large excess of recombinant PrP. 
The readout is based on 96-well plate format, where the seeds of PrPSc bind the PrPC monomer 
inducing their conformational conversion into amyloid fibrils. The fibrils are bound to 
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florescent Thioflavin-T dye (ThT), a compound known to stick all the b-sheet enriched 
aggregated molecules. The eventual increase of fluorescence is read by a shaking fluorescence 
plate reader. This method is extraordinarily efficient, leading to billion- to trillion-fold seed 
amplifications. As a result, attograms (1-18 grams) of PrPSc, which are approximately 10–40 
particles, can be detected [186, 187]. Analogous to end-point dilution titrations classically used 
in animal bioassays but with greatly reduced times and costs. 
 
 
Figure 6. The basis of RT-QuIC amplification. (Modified from [188]) 
 
Many studies conducted by different groups showed the possible use of RT-QuIC as a tool 
for ante-mortem diagnosis for human TSEs. Indeed, the ability of RT-QuIC to detect prions in 
the cerebral spinal fluid of patients with sCJD has been demonstrated [184]. Another important 
work is the one published by Zanusso and colleagues, where they detected prions in the CJD 
OM. The tissue is collected by a gentle brushing in the upper nasal cavity using flexible flocked 
swabs, without any kind of discomfort for the patients and a complete recovery of blood cells 
[189, 190]. 
This technique can also be used to detect prion diseases in many animals, such as BSE in 
cattle [191], scrapie in sheep [185], CWD in cervids [192, 193]. 
Recently, the use of RT-QuIC has been expanded to the therapeutic application. It is possible 
to control the efficacy of a treatment in a noninvasive way (OM samples) during a clinical trial. 
PrP in its normal monomeric, nonamyloid, proteinase K-sensitive form
(rPrPSen, i.e., the “substrate”) (Fig. 1). Any prion seeds in the test sample
can then recruit rPrPSen substrate molecules as they grow into larger amyloid
fibrils that are then detected by an amyloid-sensitive fluorescent dye, such as
thioflavin T. This seeded polymerization mechanism can be extraordinarily
efficient, allowing billion- to trillion-fold seed amplifications. As a result
attograms of PrPSc, representing approximately 10–40 particles, can be
detected.5,16,17 Large studies by multiple groups have confirmed the ante-
mortem diagnostic accuracy of RT-QuIC for human CJD.7,13,17–27 There
have also been many studies describing applications of RT-QuIC to the
detection and diagnosis of many animal prion diseases. Recent develop-
ents include applications of RT-QuIC to drug screening,28,29 the moni-
toring of therapeutic trials,30 a d the identification and ch racterization of
new pri n disinfectants.31 Step-wise prot cols and practical notes on
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Fig. 1 RT-QuIC seeded polymerization assay format. Prion or prion-like multimeric pro-
tein seeds in a test sample are mixed with a vast excess of monomeric substrate mol-
ecules in 96-well plates. The seeds incorporate the monomers and induce their
conformational conversion into amyloid fibrils that enhance the fluorescence of the
dye thioflavin T (ThT) as the reaction progress s in “real time.” With diluti n of the seed
sample, the lag phase prior to increase in fluorescence tends to increase and the max-
imum fluorescence decreases. The rPrP amyloid fibril model shown here is a hypothet-
ical computational model based on a parallel in-register intermolecular beta sheet
architec ure.15
377Amplified Detection of Prions and Other Amyloids
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It is also possible to perform a prescreening of compounds to check if they are able to block the 
PrPC conversion just by adding the tested compounds in the 96-well plates [194].  
 
 
1.5 Therapeutic approaches  
 
The importance to diagnose TSEs before the symptoms is fundamental to develop an 
appropriate treatment. It is known that the appearance of symptoms corresponds to an 
irreversible impairment of the brain, due to the presence of amyloid plaques, spongiosis and a 
strong astrogliosis. Indeed, there is still no therapy to cure human prion diseases. Since TSEs 
were discovered, efforts have been made to cure or at least modify the course of these 
disorders, but unfortunately the scientific community collected just failures and frustrations 
[195]. Before 2010 the interest in this field was limited, but there was a change with the 
publications of several studies proving a prion-like mechanism for all the neurodegenerative 
misfolding disorders. They proposed prion diseases as a prototype of neurodegenerative 
diseases, because there is evidence that not only the prion protein, but also other proteins such 
as Ab, a-synuclein and tau are able to aggregate and spread in AD and PD [97, 196]. This 
commonality is not irrelevant as it allows drug discovery progresses in such rare diseases with 
low public health priority and visibility. But also involving other neurodegenerative diseases 
the situation does not change much. For instance, the Food Drug Administration (FDA) has not 
approved any new treatment for these disorders since 2003, and from 2002 to 2012, 244 
compounds were evaluated in 413 trials for AD, but just 1 (Memantine) was approved for 
marketing [195]. So, it seems that in any case, the research for new possible drugs in the 
neurodegenerative field is a challenge. 
There are different reasons for this difficulty: 
- The lack of a specific diagnostic tool. As it is mentioned before, the late administration 
of a drug candidate leads directly to its failure [197]. 
- The lack of a validated target. These pathologies are not yet completely understood, so 
use as a target just the protein of interest is probable not enough [198]. 
- The blood-brain barrier (BBB) crossing. All the compounds directed to CNS need to 
cross the BBB to reach the brain, the cross efficacy has to be very high, so that the 
compounds have to arrive in a sufficient concentration to achieve their biological 
activity.  
- The treatment must be no toxic also for a long period. 
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1.5.1 Clinical trials in human TSEs 
 
The term “clinical trials” indicates biomedical and behavioral research studies to explore if a 
medical intervention is safe and effective on human patients. The medical interventions consist 
of new or repurposed drugs, psychological therapy, surgery or dietary choices [199].  
In the neurodegenerative diseases, clinical trials include two types of goals: “cure” the disease 
in the most optimistic situation or improve the patient’s lifestyle, by improving a specific 
symptom or disability. 
In prion diseases, no compound specifically designed for these disorders has been tested in 
clinical trials. There are different reasons that can explain this situation. The first one is that the 
prion diseases are a very rare illness and the costs for a clinical trial is very high, so finding a 
way to cover the expenses is not that easy. The rapidity of disease progression (for sCJD is 
around 4-6 months) is not helping too, the diagnosis and the referral to specialist centers are 
typically made late in the clinical course when patients have advanced disability, and the 
priority is palliative care. Since 1971, fourteen clinical trials have been tried, the majority of 
them are antivirals, antimalaria and antifungals [197]. 
The first compound used in TSEs clinical trials was the Amantadine. Amantadine is an 
antiviral molecule. It is not a case that it was tested prion diseases, because TSEs were initially 
considered as slow viral illnesses. Two studies were published regarding the treatment with 
Amantadine on CDJ patients during 1983 and 1984. In both cases the molecule did not show 
any kind of anti-prion activity, because there was no statistical increase of survival time 
between the treated patients and the controls [200, 201]. 
In the same period a nucleoside analog was used to treat CJD patients, the Acyclovir. 
Unfortunately, also in this case the treatment resulted to be unsuccessful [202, 203]. 
Similar negative results were obtained using other two antiviral molecule: interferon [204], 
that is a signaling protein known to induce a nonspecific resistance to  viral infection, and the 
vidarabine [205], a nucleoside analog able to bind and interfere with the synthesis of viruses.  
So, all the treatments with antivirals were negative and ineffective. 
Amphotericin B was the first antibiotic tested. This compound was previously used in two 
animal models: hamsters infected with 263K strain and CJD monkeys [206]. In both cases a 
significant increase of survival time was documented. Thus, in 1992 Masullo et al. decided to 
use this molecule to treat two CJD patients, but after 8-10 months the clinical situation of the 
patients worsened and they died [207].  
In 2001 the synergistic activity of an antidepressant (Clomipramine) and a 
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serotine/norepinephrine reuptake inhibitor (Venlafaxine) was tested in France on a vCJD 
patient. The treatment lasted for 7 weeks, but after 14 months of the symptoms onset, the 
woman died [208]. 
In the same period, Korth and others were looking for some known compounds able to cross 
the BBB. They focused the attention on some tricyclic acridine and phenothiazine molecules 
used to treat psychosis. One of them, the Quinacrine, obtained excellent results in the inhibition 
of PrPSc protein in cells chronically infected with prions (on ScN2a cells EC50=0.25 µM)  
[209]. When the compound was tested in mice models, the strong efficacy previously described 
in cells was lacking [210]. But for the good safety profile and ability to cross the BBB, the 
compound was tested in humans. The first clinical trial with Quinacrine was made in France in 
2004, 32 CJD patients were treated with 1 g dose for 1 day and followed by 300 mg daily. In 
this case, no effect was obtained [211]. [211]. In 2009, Collinge and his colleagues in UK 
opened a new trial, called PRION-1 involving 107 patients. The large majority of them were 
affected by vCJD. They noticed that 300 mg of Quinacrine were well tolerated but it was not 
sufficient to achieve the hoped results [212]. The last Quinacrine trials were performed between 
2005 and 2009 at the University of San Francisco. 425 patients were randomly treated with 300 
mg of Quinacrine or with placebo. The results of this study did not show significant differences 
between the placebo and Quinacrine treated patients [213]. In the same years, some studies 
conducted on cells demonstrated that even if Quinacrine reduces PrPSc, a continuous chronic 
treatment results in strain selection of PrP and so drug-prion resistance [214]. The combination 
of Quinacrine and another tricyclic compound, Chlorpromazine, was tested in an iCJD patient, 
but again without the expected results [215]. 
In 2003 some cases of sCJD were treated with an anticonvulsant, Phenyotin, in combination 
with Topiramate or Quinacrine and Chlorpromazine. After a short period of treatment, in both 
cases the patients started to have seizures and to increase muscle rigidity without any other type 
of improvement [216]. 
A very interesting trial came from the use of Flupirtine, a nonopioid analgesic, with an 
encouraging cytoprotective activity in prion diseases in vitro [217]. In 2004, it was used to treat 
28 patients with a probable CJD, and although tests demonstrated a slowdown of cognitive 
decline in the treated patients, there were no significantly statistic differences in the survival 
time [218]. 
Pentosan polysulfate (PSS) promotes an increase of the survival time in humans [219]. PSS is 
a semisynthetic pentasaccharide heparinoid able to act in competition with endogenous heparin 
sulfate proteoglycans as coreceptor for PrPC on the cell surface [199]. Unfortunately, it is 
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known that it does not cross the BBB, so in the all clinical trials performed, even if there was a 
strong increase in the survival time (~ 50%), there were many adverse effects due to the 
intraventricular administration [220]. 
Recently, the antibiotic Doxycycline was tested in human clinical trials with high expectation, 
after several in vitro and in vivo studies that showed its ability to reduce PrPSc, inhibit prion 
formation and destabilize aggregates, increase the mice’s incubation and survival time [221]. 
The first human study was conducted in Italy treating 21 patients with probable CJD with 100 
mg per day of Doxycycline from the diagnosis until their death [222]. A very similar trial was 
performed in Germany and in both cases the scientists noticed an increase in the survival time 
of the treated compared to the untreated (placebo treated) patients [223]. These positive results 
led to another trial conducted between Italy and France. But in this case, even if the type of 
treatment was the same, the results were not confirmed, because there were no significative 
differences between the treated and control groups [224]. A new trial started in these last years 
in Italy by Forloni et al. They are performing a preventive study with Doxycycline in patients 
with the genetic risk of developing FFI syndrome [225]. The study should end in 2023 [197].  
 
Drug Country Patient recruitment Number Primary endpoint 
Flupirtine Germany sCJD and genetic TSEs 28 ADAS-cog 
PPS UK vCJD, iCJD and genetic TSEs 7 Survival 
PPS Japan sCJD and iCJD 11 Survival 
Quinacrine France sCJD and genetic TSEs 32 Survival 
Quinacrine UK sCJD and genetic TSEs 107 Survival and rating scales 
Quinacrine USA sCJD 51 Survival 
Doxycycline France/Italy sCJD and genetic TSEs 121 Survival 
Doxycycline Germany sCJD 100 Survival 
 
Tabelle 5. Detailed information of some clinical trials. ADAS-cog, cognitive component of the AD assessment 
scale [199]. 
 
As it is possible to understand reading above, even if there have been steps forward in the 
drug development and the treatment of prion diseases, so far there is still no therapy able to 
modify the course of these disorders. 
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1.5.2 Approaches to therapy in TSEs  
 
As it is mentioned above, the drug discovery and in general the devising therapeutic 
approaches is a very challenging area in prion diseases. Nowadays, there are many different 
types of strategies.   
1.6.2.1 Repurposing approach  
In the previous chapter, it is shown that all the human trials were performed using molecules 
that were already employed for other disorders (i.e. acyclovir as antiviral). The use of existing 
drug to cure and treat new diseases is called “repurposing”. Recently, this approach has been 
commonly used to find therapies for orphan diseases, such TSEs. An orphan disease is a 
disorder that has not been adopted by the pharmaceutical industry because it is a rare disease or 
a common disease, and it is far more prevalent in developing countries than in the developed 
world. The identification of possible drug repurposing can happen by serendipity, target 
searching and observation of side effects. The advantages to use this approach are many: the 
critical information, such as drug-likeness, pharmacokinetic features, dosing, safety and 
tolerability, are already available; the time saved, because in this way it is possible to avoid 
several years of the drug development; the lack of human risk in terms of side effects [226, 
227]. 
The most common strategy used to do drug repositioning is the in silico screening of 
compound libraries for new targets. In-silico term refers to a mathematical equation able to 
explain a biological phenomenon. It is quite common in the drug repositioning for prion 
diseases to use a quantitative structure-activity relationship (QSAR) model to screen a huge 
library of compounds in order to select only the molecules that have a good predicted 
biological activity and then confirm the result with in vitro studies [228]. 
 All the compounds used in clinical trials for prion diseases represent a good example of drug 
repurposing [195]. 
 
1.5.2.2 The use of small molecules to block the prion replication 
Another possible approach is to use compounds that can block the prion replication. From the 
knowledge of prion cell biology, this blocking could happen in a direct mechanism by which 
the compound induces the stabilization of PrPC and/or the destabilization of PrPSc; or by an 
indirect mechanism, by which the molecule interacts with other components of the prion 
replication. It is not so easy to identify compounds with these abilities, but even if they are 
obtained, they still face high hurdles to qualify as drug candidates. Because they also need to 
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reach the appropriate cellular compartment, have an acceptable ratio of toxic to therapeutic 
dose and the capacity to cross the BBB effectively [195]. Designing molecules with a 
deliberate activity, is a task for the computational chemists. Once the molecules are designed 
and computationally screened, they are tested in cell lines chronically infected with prions (next 
chapter) and in vitro experiments to confirm their activity and mechanism of action. If the 
ability of the compound to clear the level of PrPSc is really good and it is not toxic, the 
compound could be tested in an animal model, usually mice or hamsters.  
Starting from the fact that the structure of PrPSc is poorly defined, they can have different 
strains [229], the chaperones and other proteins involved in the prion replication are not so well 
known, the most sensate approach is to target PrPC [230]. On the cellular prion protein, there 
are some binding sites, where a molecule can stick and block the contact with PrPSc, thus 
avoiding the prion conversation and propagation. Below there is a list of chemical scaffolds 
reported to have an anti-prion activity binding PrPC (Figure 7): 
• Acridine and phenothiazine were chosen by Korth in 2001 as possible anti-prion 
candidates for their ability to cross the BBB. In prion infected neuroblastoma mice 
cell line (ScN2a), the two molecules that exhibited a strong activity were Quinacrine 
(EC50=0.3 µM) and Chlorpromazine (EC50=3 µM) [209, 231]. Unfortunately, neither 
one of these two have the same activity in an animal model (or a human). For the 
Quinacrine, it is due to the fact that this molecule reaches the brain in a low 
concentration [214]. NMR and SPR studies demonstrated the ability of Quinacrine to 
bind the globular domain of human recombinant PrP (residues 121-230) [232]. Recent 
articles showed that Chlorpromazine does not have a strong binding with PrPC (KD > 
400 µM) and that the anti-prion activity is mainly due to its capability to promote a 
relocalization of the PrPC from the cell membrane [233, 234]. 
• In the beginning of 2000s, Caughey and its collaborators screened cyclic tetrapyrroles. 
They consist of a planar aromatic ring scaffold, able to coordinate metal ions. One of 
them, the cationic tetrapyrrole Fe(III)-TMPyP was shown to have an EC50=1.6 µM in 
RML-PK1 cells and to bind the globular domain of PrPC with a KD=4.52 µM [235, 
236]. But Fe(III)-TMPyP is not prone to cross the BBB, so it was not tested in an 
animal model [237]. 
• GN8 is a derivate of the Diphenylmethane. This molecule was identified through an 
in-silico screening design to select compounds able to bind the PrPC. In vitro 
experiments determined the binding of GN8 to the residues 159 and 196 of PrPC C-
terminal domain and EC50=1.35 µM in cells [125]. It has been shown that GN8 and 
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some of its derivatives have the ability to prolong the survival time in prion-infected 
mice [238]. The results obtained in both in vitro and in vivo experiments failed to 
confirm its anti-prion activity and ability to bind PrPC [230]. 
 
 
Figure 7. Proposed binding regions on PrPC of the different compounds. (Modified from [230]) 
 
 
1.5.2.3 Immunotherapy 
Both active and passive immunization approaches in AD have been shown to clear the Ab 
misfolded protein. These results suggested to apply the immunization strategy in prion diseases. 
The challenge in this field is the self-tolerance for the PrPSc, because it is just a modified form 
of PrPC.  
The active immunization led to a prevention of prion diseases in a mouse model, using an 
oral administration with PrPC expressed in an attenuated Salmonella vector. Sadly, it has been 
shown that the use of this strategy could result in adverse effects, such as autoimmune 
meningoencephalitis and degeneration in hippocampal and cerebellar neurons. While the 
passive approach seems to prolong the survival time just when it is administered before or 
immediately after the exposure to PrPSc [239, 240]. 
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1.5.2.4 PrPC silencing and activation of Unfolded Protein Response pathway 
Assuming that Prnp knockout mice are resistant to prion infection, another proposed 
approach, in literature, is the PrPC silencing. In 2008, Mallucci’s group used lentivirally 
mediated RNAi for treatment of prion infected mice. Even if localized to the hippocampus, a 
single administration of these viruses increases the lifespan of the mice, protects neurons from 
degeneration, reduces prion accumulation and prevents the onset of behavioral dysfunction 
[241]. 
The same group focused the attention also to the unfolded protein response (UPR) pathway, 
that is a cell protective mechanism which acts to restore the level of the proteins in the face of a 
misfolding load, reducing the protein synthesis through the activation of PERK enzyme. In 
2013, they treated prion infected mice with GSK2606414, a PERK inhibitor. This treatment 
prevents UPR-mediated repression and promoting the neuroprotection, it abolishes the 
development of clinical prion diseases in infected mice [242].  
 
 
1.6 Experimental models  
 
For the discovery of new anti-prion drugs, cell cultures are considered as the most relevant 
first screening step. Over the last twenty years, many groups of scientists have attempted to 
find cellular cultures supporting prion diseases agent replication. In addition to the advantages 
of screening drugs with potential therapeutic values, cell cultures can analyze the biological 
properties of PrPC and PrPSc, have the possibility to determine the nature of the infectious 
agent, the factors governing its propagation and the biological markers of the infection. 
The direct approach to propagate prions ex vivo consists of putting the infectious agents in 
contact with the cell and checking whether replication occurs. The simplest way to obtain the 
infectious agents is to extract them from infected brain homogenates. The infectious fraction is 
pretreated for 30 min at 80°C and sonicated to reduce the risk of transmitting conventional viral 
and bacterial agents. After exposure to the culture, cells are washed and split several times. To 
check whether replication is occurring, it is necessary to test for the generation of new 
molecules of PrPSc. Several techniques are used to detect the presence of PrPSc. The most 
common one is the SDS-PAGE analysis of cell lysates treated with protease K, followed by 
Western blot analysis using anti-PrP antibodies.  
There are different strains of prion protein depending on the species of origin, which can 
reduce the effectiveness of prion propagation. To avoid this species-barrier phenomenon, the 
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PrPSc present in the inoculum has the same species origin as the one expressed by cultured 
cells. In 1970 the group of Clarke [243] was the first to infect TSE culture cells successfully, 
followed by the groups of Chesebro [244] and Prusiner mainly using mouse neuroblastoma 
N2a cell lines [245]. Still today N2a is the most common cell line used. Another widely used 
one is the hypothalamic cell line called GT1. These cells are well differentiated, originate from 
the central nervous system and are established from gonadotropin-releasing hormone neurons 
immortalized by genetically targeted tumorigenesis in transgenic mice. Many other cells are 
prion-susceptible, as shown in Table 8. From different published works, it is possible to 
conclude that: only some strains can replicate in one particular cell line, only some cells from 
culture become infected and sub-cloning could improve the susceptibility to prions, the PrP 
expression level is an important factor for the detection of a successful infection, the 
propagation of prions induces only subtle changes in the phenotype of cultures. 
As mentioned above, the cell culture model is largely used to carry out a prescreening test of 
potential anti-prion drugs. The advantage of cell culture screening is crucial, since it is not 
possible to begin the screening in vivo using a huge library of compounds. Therefore, cell 
screening assay makes it possible to identify a reasonable number of in vitro active molecules 
to use for in vivo experiments [246]. 
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1.7 Aims of the research  
 
The absence of a therapy to cure prion diseases is an active field of research. Not only for 
these disorders but especially because TSEs are now considered as the prototype of 
neurodegenerative diseases. This challenge is due to many factors, such as the difficulty to 
diagnose the disease in a pre-symptomatic stadium, to develop a molecule able to cross the 
BBB and still be efficient and to detect the most appropriate targets. As mentioned above, the 
two main targets used to block the prion conversion are the stabilization of the PrPC and the 
destabilization of the PrPSc. In-silico approach is one of the most common strategies for drug 
discovery of prion diseases, used before the in vitro studies to detect compounds that can 
satisfy specific requirements, such as a possible binding of molecule to the target or the need to 
have a precise biological activity. 
 
In the present thesis, a specific strategy to identify a compound as a possible anti-prion agent 
has been investigated. In particular the objects of this thesis are: 
 
• In vitro identification of a hit compound, starting from a library (Figure 8) of ten 
molecules. The library was selected using a Quantitative-Structure Activity-
Relationship (QSAR) model, built by Dr. Rossetti and Dr. Carloni, able to measure 
the predicted IC50 of the compounds. The in vitro screening started with the evaluation 
of the cell viability of each compound and then with the analysis of anti-prion activity 
of the compounds measured by the inhibition of PrPSc level in cell lines chronically 
infected with prions. 
 
• Understanding the possible mechanism of action of the hit compound. From the 
literature, it is known that the many compounds with a strong anti-prion activity in 
vitro are the ones able to bind the cellular prion protein. The reason is not known, but 
a possibility is that these compounds bind the PrPC in the same binding site of the 
PrPSc, thus decreasing the prion conversion rate. Also, targeting another component of 
the prion conversion is a very good strategy, even if the other proteins involved in the 
conformational change are still not completely known. 
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Figure 8. Library of the selected compounds tested in vitro. 
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CHAPTER II 
 
 
 
MATERIAL AND METHODS 
 
 
2.1 Computational details 
 
Note: Computational analysis were performed at the Jülich Research Centre (Stetternich 
Forest, Kreis Düren, Germany) by Dr. Giulia Rossetti and Dr. Paolo Carloni. For this reason, 
the related Materials and Methods have been moved to the Appendix II.  
 
 
2.2 Compound synthesis  
 
Note: Selected compounds were provided by Mcule.com, that is an online drug discovery 
platform.  
 
 
2.3 Biological evaluation 
 
In vitro assessment of in silico selected compounds. 
 
 
2.3.1 Cell culture 
 
Mouse neuroblastoma cell line, either the non-infected (N2a) and the chronically infected 
with Rocky Mountain Laboratory (RML) or with 22L prion strain (ScN2a), were grown in 
Minimal Essential Medium (MEM)-1% L-glutamax complemented with 10% fetal bovine 
serum (FBS), 1% non-essential amino acids (NEAA), and 1% penicillin-streptomycin. 
Immortalized mouse hypothalamic neurons (GT1) and chronically infected ScGt1 cells, with 
both RML and 22L prion strains, were grown in Dulbecco’s modified Eagle’s medium 
(DMEM)-1% glutammax supplemented with 10% FBS and 1% penicillin-streptomycin.  
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All cell lines were cultivated in 25 cm2 flasks at 37 °C under 5% CO2 or in 10 cm2 Petri 
dishes. 
 
 
2.3.2 Compounds 
 
All the compounds were dissolved in 100% dimethyl sulfoxide (DMSO), to a 10 mM stock 
solution. From these stock solutions, intermediate dilutions were prepared as needed. For cell 
treatment, stock solutions were further diluted in 100% Ethanol (EtOH) to a final concentration 
of 1 mM. Each compound was then diluted in cell culture medium. In the cell medium, the final 
concentration of DMSO was never above 0.1%. Detailed treatment conditions are provided in 
following methods. Mock controls were treated with vehicle only under the same conditions.  
 
 
2.3.3 Assessment of cell viability  
 
N2a, N2a chronically infected with RML or 22L prion strain (ScN2a), GT1 and GT1 
chronically infected with RML or 22L prion (ScGT1) cells, were maintained in culture and 
grown to 80% confluence. The medium was changed and the cells were detached.  
The cell density was determined by cell counting using ScepterTM 2.0 Cell Counter 
(Millipore). The cell density was adjusted to 2.5 × 104 cell/mL with MEM (N2a, ScN2a) or 3 × 
104 with DMEM (GT1, ScGT1). 
The cell suspension was added to each well of a 96-well, tissue culture-treated, clear bottom, 
plate (Costar) and the cells were allowed to settle for 1 day at 37 °C under 5% CO2 prior to the 
addition of the compounds. 
Each compound (dissolved in EtOH) was diluted in the cell medium to a final concentration 
of 0.1, 1 and 10 µM. After 24 h, cell culture medium was removed and replaced by compound-
containing medium.  
The plate was incubated at 37 °C under 5% CO2 for 5 days. 
 
2.3.3.1 MTT assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, SIGMA) was 
diluted in phosphate buffer solution (PBS) to a working dilution of 5 mg/mL.  
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The medium was then removed, and the cells were incubated with the MTT solution for 3 h at 
37 °C under 5% CO2.  
After incubation, a solution of DMSO/2-Propanol (1:1) was added to each well and the plate 
was kept at room temperature (RT) for 30 min before reading. The emission intensity was 
quantified using a Spectramax Gemini EM (SoftMax Pro). 
 
2.3.3.2 Cell counting KIT-8 
Ten µM of CCK-8 solution (ST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4- 
disulfophenyl)-2H-tetrazolium, monosodium salt) (Dojindo Labroatories) were added to each 
well of the plate.  
The plate was then incubated for 4 hours in the humidified incubator (e.g., at 37°C, 5% CO2). 
After that, the absorbance was measured at 450 nm using the microplate reader (Spectramax 
Gemini EM SoftMax Pro). 
 
 
2.3.4 PrPSc and PrPC detection in cell lysates by western blotting 
 
After the treatment with compounds, the amount of PK-resistant PrPSc was measured in 
ScN2a and ScGT1 treated with 1 µM of concentration of each compound, then with a titration 
for compound 1. After 4 days of treatment, the accumulation of PrP protein was detected by 
immunoblotting of lysed cells before and after PK digestion.  
 
2.3.4.1 Cell lysates  
After removing the medium and washing the cells with PBS, 350 µL of lysis buffer (10 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 0.5% nonidet P-40, 0.5% deoxycholic acid sodium salt) were 
added to the flasks/dishes, then the cells were detached using a cell scraper (Falcon) and the 
lysates were collected and pelleted by centrifugation at 2000 rpm for 10 min at 4 °C in a bench 
microfuge (Eppendorf).  
 
2.3.4.2 Protein quantification 
The total protein amount of the samples was measured by bicinchoninic acid assay (BCA) 
(Pierce).  
First, it was necessary to prepare the Albumin Standards that were used at 1000, 1500 and 
2000 µg/mL concentrations, and the Working Reagent (WR). The total volume made depended 
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on the number of samples and standards to be quantified. The volume was calculated with the 
following formula: 
(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR 
 
i.e. (3 standards + 8 unknowns) x (3 replicates) x (100 µL) = 3300 µL of WR 
Generally, there were three replicates. 
The WR volume was prepared mixing 50 parts of BCA reagent A with 1 part of reagent B 
(50:1). A 96-well plate was loaded with 5 µL of Blank (distilled water), Albumine Standards 
and samples (cell lysates) with 100 µL of the Working Reagent mix.  
The plate was incubated for 20 minutes at 37°C and then the absorbance was read with 
SpectraMax reader and the proteins were quantified. 
 
2.3.4.3 PK digestion 
Two hundred and fifty µg or 500 µg of protein were digested with 10 µg of PK (Roche) for 1 
h at 37 °C.  
The reaction was arrested with 2 mM of phenylmethylsulphonyl fluoride (PMSF, SIGMA) 
and the PK-digested cell lysates were centrifuged at 55000 rpm for 75 min at 6°C in an 
ultracentrifuge (Beckman Coulter). 
After the centrifugation, the supernatants were discarded, and the pellets were re-suspended 
in 2X or 5X sample loading buffer (125 mM Tris HCl, pH 6.8, 10% 2-mercapethanol, 4% SDS, 
0.2% bromophenol blue, 20% glycerol and 200mM DTT) and boiled for 10 min at 100 °C. An 
amount equal to 30 µg of total proteins was used for the non-PK-digested samples, boiled for 
10 min.  
 
2.3.4.4 SDS-page assay and immunoblotting 
Samples were loaded onto a 12% Tris-Glycine SDS-PAGE gel for protein separation, then 
they were transferred to a nitrocellulose membrane (GE Healthcare).  
The membrane was blocked with 5% non-fat milk in TBST (Tris 200 mM, NaCl 1.5 mM, 1% 
Tween-20) for 1 hour at RT and incubated with 1 µg/mL anti-PrP Fab W226, diluted in 
blocking solution, overnight at 4 °C. After three washes with TBST, the membrane was 
incubated for 1 h a RT with secondary antibody (goat anti-mouse IgG F(Ab)2 conjugated with 
horseradish per- oxidase (HRP), DAKO) diluted 1:1000 in blocking solution. After several 
washes, the signal was detected using enhanced chemiluminescent system (ECL, Amersham 
Biosciences) and Uvitec Alliance (Cambridge).  
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Densitometric analysis was performed using Uviband Analysis Software. 
 Data are expressed as mean ± SD, and the values of the controls are adjusted to 100%.  
 Each experiment was performed in triplicate.  
 
2.3.4.5 PrPC detection in cell lysates by western blotting 
The same treatment conditions reported above were used for non-infected N2a and GT1 cells. 
After 5 days of drug treatment, the amount of PrPC was measured by immunoblotting of lysed 
cells. Thirty µg of total proteins were used for the analysis. Same protocol as above was used, 
without PK digestion step. Each experiment was performed in triplicate.  
 
2.3.4.6 PrPSc quantification by ELISA assay 
PK digestion of cell lysates was performed as described above. After ultracentrifugation, 
pellets were dissolved and denatured in 50 µL of 8 M guanidine hydrochloride (GdnHCl) in 
coating buffer (0.1 M sodium bicarbonate, pH 8.2) for 1 h and diluted into 500 µL of coating 
buffer.  
Twenty µL of the suspension were transferred to 96-well MaxiSorp ELISA plates (Nunc), 
with each well containing 180 µL of coating buffer and the plates were sealed and incubated 
overnight at 4 °C. To increase the immuno-reactivity of PrPSc, coated proteins were denatured 
in situ. Fifty µL of 8 M GdnHCl were added to each well and incubated for 10 min at room 
temperature. The ELISA plates were washed three times with TBST and blocked with 200 µL 
of 3% BSA in TBS (20 mM Tris-HCl, 137 mM NaCl, pH 7.5) for 1 h at 37 °C. After three 
washes with TBST, the plates were incubated with 100 µL of anti-PrP antibody W226 (1.5 
µg/mL) in 1% BSA/TBS, at 37 °C for 2 h. After seven washes with TBST, 100 µL of goat anti-
mouse IgG Fab conjugated to HRP diluted 1:1000 in 1% BSA/TBS were added to the plates 
and incubated at 37 °C for 1 h. Again, plates were washed seven times with TBST, and then 
developed with 100 µL of 1-step TMB (3,3′,5,5′- tetramethylbenzidine) Turbo ELISA HRP 
substrate (Pierce).  
The reaction was stopped by the addition of 100 µL of 2 M sulfuric acid to the plates. 
Absorbance at 450 nm was measured using a microplate reader (VersaMax, Molecular 
Devices). Dose-response curves and IC50 values were computed using IGOR (Demo Version 
6.32). 
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2.3.5 PNGase F treatment 
 
PNGase F treatment were performed on N2a cell lysates. 
Thirty µg of protein were incubated with 1 µL of Glycoprotein Denaturating Buffer (10X) 
and water to reach a total reaction volume of 10 µL. Then, the mix is heated at 100 °C for 10 
minutes to denature the protein. 
The denatured protein was then chilled on ice and centrifuged for 10 seconds. The solution 
was filled with 2 µl of GlycoBuffer 2 (10X), 2 µl of 10% NP-40 and 6 µl of H2O. One µl of 
PNGase F was added and the mix was mixed very gently. The solution was incubated with 
shaking (350 rmp) at 37°C for 6 hours. 
The result was, then, observed by SDS-page. 
All the reagents for the protocol were assessed by New England BioLabs. 
 
 
2.3.6 Ammonium chloride treatment 
 
N2a RML infected cells were treated in absence or in presence of 4 µM of compound 1 with 
20 mM of NH4Cl. The ammonium chloride at this concentration is known to block the 
lysosomal activity. The results of the treatment were then observed by SDS-page. 
 
 
2.3.7 Recombinant full-length mouse PrP production and purification 
 
The mouse construct was expressed in competent BL21 Rosetta2 (DE3) cells Escherichia 
coli (Stratagene). 
Freshly transformed overnight culture was inoculated into Luria Bertani (LB) medium and 
100 µg/mL ampicillin and 30 µg/mL chloramphenicol. At 0.8 OD600 expression was induced 
with isopropyl b-D galactopyranoside (IPTG) to a final concentration of 1 mM. Cells were 
grown in a BioStat-B plus fermentor (Sartorius). The cells were lysed by a homogenizer 
(PandaPLUS 2000) and the inclusion bodies were suspended in buffer containing 25 mM Tris-
HCl, 5 mM EDTA, 0.8% TritonX100, pH 8, and then in bi-distilled water several times. 
Inclusion bodies containing MoPrP (23-231) were dissolved in 5 volumes of 8 M guanidine 
hydrochloride (GdnHCl), loaded onto pre-equilibrated HiLoad 26/60 Superdex 200-pg column, 
and eluted in 25 mM Tris–HCl (pH 8.0), 5 mM ethylenediaminetetraacetic acid, and 5 M 
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GdnHCl at a flow/rate of 1.5 mL/min. Protein refolding was performed by dialysis against 
refolding buffer [20 mM sodium acetate and 0.005% NaN3 (pH 5.5)] using a Spectrapor 
membrane (molecular weight, 10000). Purified protein was analyzed by SDS-polyacrylamide 
gel electrophoresis under reducing conditions and Western blot. 
 
 
2.3.8 Competition assay 
 
A mix of recombinant mouse full length PrP (23-231) and compound 1 was incubated at 37 
°C in 350 rpm of shaking for 30 minutes. 
The mixes were different:  
• PrP : compound 1 = 1:1 = 1µM : 1µM 
• PrP : compound 1 = 2:1 = 2µM : 1µM 
• PrP : compound 1 = 1:2 = 0.5 µM : 1µM 
• PrP : compound 1 = 1:5 = 0.2 µM : 1µM 
After 1 hour, the mix and the other treatments (compound 1 alone) were centrifuged many 
times at 2000 rpm in Nanosep centrifugal device (Merk) with Omega membrane 3 kDa to pass 
the whole solution through. These tubes are permeable to compound 1 (416.93 Da) but not to 
the PrP (25 kDa) and to the PrP-compound 1 complex.  
The mix and the other treatments were added to the cells as a normal treatment for 4 days. 
Then the cells were lysed, and the result is observed by SDS-page.  
 
 
2.3.9 RT-QuIC procedure  
 
After purification, aliquots of the recombinant PrP (23-231) were stored at −80 °C in 10 mM 
phosphate buffer (pH 5.8). Before each test, the protein solution was allowed to thaw at room 
temperature and filtered using Millex-GV filter 0.22 µm (Millipore).  
The final reaction volume was 100 µL loaded into the plate (ViewPlate-96 F TC/50x1B, 
Perkin Elmer) and the reagents (Sigma) were concentrated as follow: 150 mM NaCl, 0.002% 
SDS, 1X PBS, 1 mM EDTA, 10 µM ThT and 0.2 mg PrP ml−1. 
The seed consists of sonicated RML-N2a cells. Before the sonication the cells were collected 
in 100 µl of PBS 1X, after the sonication the sample was quantified using the BCA assay, in 
order to use it as a seed (1 µg of the protein). 
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After the addition of 10 µL of seed, the plate was sealed with a sealing film (Perkin Elmer) 
and inserted into a FLUOstar OPTIMA microplate reader (BMG Labtech). The plate was 
shaken for 1 minute at 600 rpm (double orbital) and incubated for 1 minute at 45 °C. 
Fluorescence readings (480 nm) were taken every 30 minutes (30 ashes per well at 450 nm). 
Given the rapid response, a specific threshold was set to decrease the likelihood of false 
positives. A sample was considered positive if the mean of the highest two fluorescence values 
(AU) of the replicates was higher than 10.000 AU and at least two out of three replicates 
crossed the threshold that was set at 30 hours. This reaction cutoff was established because in 
all the experiments there were wells only with PrP (23-231) and in these cases no positive RT-
QuIC reactions were observed until after 30 hours. 
 
 
2.3.10 Immunofluorescence of fixed cells, the surface staining  
 
N2a cells were seeded to semi-confluence in each well of a 24-well plate containing a poly-
lysine coated coverslip and an appropriate culture medium coverslip for 24 hours.  
After one day of incubation the cells were put on ice for 15 minutes. 
Then the cells were stained with the primary antibody (W226 1:200) in culture medium for 
20 minutes, always in ice. After this time, the medium was removed, and the cells were washed 
2 times with PBS. 
The cells were then removed from the ice and were fixed using 4 % of para-formaldehyde 
(PFA) for 20 minutes. The PFA was discharged and the cells were washed 3 times for 5 
minutes with PBS.   
Blocking buffer, consisting of 7% Normal Goat Serum (NGS) in PBS, was added to the cells 
for 1 hour at room temperature. After the blocking, the cells were incubated with a secondary 
antibody (Goat anti-mouse [GαMo]-AlexaFluor488, Life Technologies) diluted 1:1000 in the 
incubation buffer (1% NGS, 0.02% triton-100 in PBS) for 1 hour at room temperature in the 
dark. 
After 2 washes of 5 minutes in PBS, the cells were incubated with 0.1-1 µg/ml of DAPI (Life 
Technologies) in PBS-T for 5 minutes. 
The cells were washed 3 times in PBS for 5 minutes and then the coverslips were mounted 
with a drop (around 4 µL) of Fluoromount-G (Invitrogen). The coverslips were sealed with nail 
polish to prevent drying and movement under the microscope. 
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Images were acquired with C1 confocal microscope (Nikon). FITC filter was used for detection 
of PrP specific staining, while Dapi specific staining was acquired with 500 nm filter. 
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CHAPTER III 
 
 
RESULTS 
 
 
3.1 In silico screening 
 
The in silico screening was performed using a QSAR model to select a small library of 
molecules with precise features, such as specific biological activity. The model generation, 
validation and the virtual screening were done in the Jülich Institute (shown in the related 
Results chapter Appendix I, Section II).  
The in silico screening led to a library of 10 molecules (Figure 8), the majority of which are 
acridine and phenothiazine derivatives. The selection of the compounds was made by 
calculating the predicted IC50 (pIC50) with the QSAR model. The pIC50 of each compound is in 
the nanomolar range (Table 6). 
 
Compound pIC50 (nM) 
1 54.9 
2 63.9 
3 80.1 
4 128.8 
5 130.2 
6 168.0 
7 170.7 
8 177.9 
9 184.2 
10 184.6 
 
Table 6. The predicted IC50 of compounds selected with the virtual screening. 
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3.2 Anti-prion effect of the library on N2a-RML cell line 
 
The in vitro screening was mainly performed using the neuroblastoma mice cell line 
chronically infected with RML prion strain.  
The screening was performed to assess the ability of the compounds to have an anti-prion 
activity. The ability of all compounds to reduce PrPSc level was determined by Western blot 
densitometry of the PK resistant PrPSc. After a PK digestion, it is possible to observe only the 
presence of resistant PrPSc bands (PrP27–30), while without PK treatment both PrPSc and PrPC 
bands are present (Figure 3). The first assessment of the compounds’ anti-prion activity was 
performed at just one concentration, 1 µM. 
 
 
3.2.1 Cell viability on N2a-RML cell line 
 
In the beginning, we determined the effects of the library compounds on cell viability using 
two different assays: MTT assay and the CCK-8 kit. They are both sensitive colorimetric 
assays able to assess the cell metabolic activity, however, they use two different tetrazolium 
dyes. In the MTT assay, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is 
reduced by NAD(P)H-dependent cellular oxidoreductase enzymes to its insoluble formazan, 
that gives a purple color. While the CCK-8 kit uses the WST-8 [2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt], which is reduced in 
a formazan dye upon the reduction with a dehydrogenase, giving an orange color [247].  
The treatment concentration was evaluated at 1µM. In Table 7 results for each compound are 
reported. Compound toxicity is expressed as an average percentage of viable cells treated with 
the compound, versus control cells without the compound or just with the vehicle. No toxicity 
was observed in the selected library, using both techniques. The toxicity threshold at this 
concentration was set below 80%, as it has already been shown in the literature  [248].  
 
 
3.2.2 Inhibition of PrPSc replication at a concentration of 1 µM  
 
None of the compounds showed cytotoxic effects, so all of them were tested in N2a-RML 
cells to quantify the presence of PrPSc protein after the treatment. The ability of compounds to 
reduce the level of the resistant PrPSc in prion-infected cells was determined by Western blot 
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densitometric analysis. Relative amount of PK-resistant PrPSc was measured in N2a-RML cell 
lysates.  
Although the measured pIC50 of each of the compounds was in the nanomolar range, almost 
none of them showed a strong anti-prion activity at the concentration of 1 µM. 
All the treated samples were normalized to the untreated control (Ctrl). The cells treated with 
the maximum concentration of the solution in which the compounds were dissolved (Mock) 
were not subjected to a change in the PrPSc level. Compounds 3, 4, 5, 7, 8 and 10 in all four 
independent experiments did not promote a decrease in the level of PrPSc protein. Compounds 2 
and 9 turned out to have mild anti-prion activity, while treating N2a-RML cells with compound 
1 resulted with a strong clearance of PrPSc. Indeed, the level of the PK-resistant prion protein in 
this case was around 35%, with respect to the control. (Figure 9 and table 8). 
 
Compound MTT assay CCK-8 Kit 
Ctrl 100 100 
Mock 102.3 ± 4.7 98.3 ± 5.3 
1 90.0 ± 3.2 87.4 ± 3.4 
2 91.1 ± 7.6 89.1 ± 5.6 
3 102.9 ± 1.9 100.3 ± 4.8 
4 82.6 ± 8.1 82.4 ± 1.2 
5 85.8 ± 5.3 93.1 ± 4.6 
6 80.1 ± 2.7 83.2 ± 6.2 
7 94.2 ± 0.4 87.5 ± 3.9 
8 94.9 ± 1.3 91.2 ± 4.0 
9 83.5 ± 1.7 80.3 ± 1.6 
10 80.6 ± 3.4 82.3 ± 4.5 
 
Table 7. Cell viability values at 1µM treatment. Values are the mean of three experiments, standard deviations are 
given. 
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Figure 9. Anti-prion effect evaluation of all compounds at 1 µM of concentration. (A) Western blot of N2a-
RML cell lysates depicting the presence or absence of prions following the treatment with the compounds before 
(down) or after (up) PK digestion. The proteinase-K digested cell lysates were detected with W226 anti-PrP 
monoclonal antibody. Bands represent di-, mono-, and un-glycosylated isoforms at approximately 32, 23 and 18 
kDa, respectively. (B) Bar graph representations of the percentage of PrPSc infectivity compared to non-treated 
control. Error bar is ± standard deviation of four independent experiments. 
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Compound −PK +PK 
Ctrl 100 100 
Mock 92.4 ± 7.2 94.0 ± 8.1 
1 55.7 ± 6.3 35.6 ± 8.8 
2 63.8 ± 6.0 70.9 ± 17.3 
3 92.5 ± 8.9 94.4 ± 12.8 
4 92.6 ± 11.1 108.6 ± 19.3 
5 95.6 ± 12.1 82.3 ± 18.0 
6 109.5 ± 20.4 101.7 ± 3.1 
7 99.6 ± 20.7 82.4 ± 11.8 
8 69.1 ± 3.5 85.4 ± 12.1 
9 83.5 ± 14.0 77.1 ± 17.3 
10 85.8 ± 11.6 88.0 ± 19.9 
 
Table 8. Effect of test compounds on PrPSc level in N2a-RML cells. N2a-RML cells were incubated with each 
compound for 5 days. The values under –PK and +PK represent the percentage of the level of total amount of PrP 
(–PK) and of PrPSc (+PK) normalized to the control (100%). The values after ± are the standard deviations (SD) 
calculated from the four independent experiments performed. 
 
 
3.3 Anti-prion activity of Compound 1 on N2a-RML cells 
 
The results obtained from the anti-prion activity of the whole library on N2a-RML cell 
revealed a strong effect of compound 1 at 1 µM of concentration. Observing the structure of 
this molecule, it is immediately evident that compound 1 is a phenothiazine derivative. In 2001 
Korth and his collaborators tested this moiety on the same cells [209]. They found that this kind 
of tricyclic compounds, as acridines, have a good anti-prion activity. It was believed that the 
effect was due to the their binding to the C-terminal domain of PrPC [233]. However, a recent 
study [234] demonstrated the ability of some phenothiazines, as Chlopromazine, to promote the 
relocalization of the cellular PrP from the cell surface to the intracellular compartments. 
We decided anyway to proceed with compound 1 and calculate its IC50 (the half minimal 
inhibitory concentration) on N2a-RML cells. Before that, we measured the cell viability of 
compound 1 at many different concentrations and its non-toxic profile was confirmed with the 
cell viability assays (Figure 9).  
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Concentration (µM) MTT assay  CCK-8 Kit 
0 100 100 
0.1 100.4 ± 2.7 101.5 ±1.4 
0.2 102.0 ± 5.0 98.4 ± 2.5 
0.4 98.1 ± 4.9 99.6 ± 3.8 
0.6 92.4 ± 1.5 97.5 ±5.4 
0.8 89.4 ± 3.1 92.2 ± 7.5 
1 90.0 ± 3.2 87.4 ± 3.4 
2 87.9 ± 7.9 95.6 ± 3.2 
4 98.7 ± 9.6 87.4 ± 9.1 
10 89.1 ± 0.7 89.4 ± 7.1 
 
Table 9. Effect of compound 1 on cell viability of N2a-RML at different concentrations. The values represent the 
% of the viable cells.  
 
 
Figure 10. IC50 evaluation of compound 1 on N2a-RML. (A) Dose-response curve form ELISA assay of 8 
different concentration of compound 1. (B) Western blot of N2a-RML cell lysates treated with compound 1 at the 
same concentrations used in (A), after digestion with proteinase K. 
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The IC50 was calculated with the ELISA assay, using PK digested samples from N2a-RML 
cells treated with eight different concentrations of compound 1 (0, 0.2, 0.4, 0.6, 0.8, 1, 2, 4 
µM). The results obtained were then confirmed by western blot analysis, using the same PK-
digested samples. Each of the two experiments were repeated three times. This experiment 
established the anti-prion activity of compound 1, the IC50 (calculated with IGOR software) 
0.42 ± 0.1 µM (Figure 10). 
 
 
3.3.1. Anti-prion activity of compound 1 on different cell lines and prion strains 
 
It is known from the literature that several small molecules are active only on precise cell 
lines and on some prion strains and not on others, these phenomena are called cell and strain 
specificity [249-251]. Given the fact that the exact mechanisms of action for any anti-prion 
compound are unknown, it is not easy to explain the reason, in terms of molecular basis, to 
explain these two aspects. The strain specificity happens probably with compounds that exert 
their interaction by directly binding to PrPSc, since the strain specificity seems to derive from 
differences in PrPSc.[252]. 
Starting from the fact that the mechanism of compound 1 as an anti-prion agent is unknown, 
we decided to test whether at least at high concentrations the interested molecule has the same 
ability to clear the scrapie prion protein on three other cell lines: N2a chronically infected with 
22L mouse prion strain (N2a-22L), hypothalamic mouse cell line (GT1) infected with two 
prion strains, GT1-RML and GT1-22L. 
In Figure 11 (A), the western blots of cell lysates of the previously mentioned cell lines 
infected with two different prion strains treated or untreated with compound 1 are represented. 
As it was already shown in the IC50 experiments, 4 µM of compound 1 in N2a-RML can bring 
the level of PrPSc to around 9.4%, meaning that it promotes a strong clearance of PrPSc. This 
activity is maintained in the other cell lines, the treatment on N2a-22L reduces the level of 
PrPSc around 5% compared to the untreated sample and around 10% in the GT1-RML and GT1 
22L cells (Figure 11 B). Even if it seems to be a bit lower, the total amount of PrP (samples 
nontreated with proteinase K) also seems to be reduced in all the cell lines. This reduction is 
probably due to the clearance of PrPSc visible in the PK-treated samples.  
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Cell line Concentration (µM) −PK +PK 
N2a-RML 
0 100.0 100.00 
4 62.1 ± 3.4 9.4 ± 2.8 
N2a-22L 
0 100.0 100.0  
4 48.7 ± 12.4 5.1 ± 4.5 
GT1-RML 
0 100.0 100.0 
4 42.0 ± 3.8 12.3 ± 5.3 
GT1-22L 
0 100.0 100.0 
4 39.2 ± 9.6 11.0 ± 8.0 
 
Figure 11. Activity of compound 1 on the total PrP or rPrPSc on N2a-22L, GT1-RML, GT1-22L. (A) One of 
the three WBs carried out using the cell lysates of treated and untreated cells with compound 1, before or after PK 
digestion (B) Quantification of the three independent experiments performed. The values under –PK and +PK 
point the percentage of the level of the total amount of PrP (–PK) and of PrPSc (+PK) normalized to the control 
(100 %). The values after ± are the standard deviations (SD) calculated from the four independent 
experiments performed. 
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In order to perform this experiment, before the treatment cells were counted and seeded in the 
same number to administer the compound 1 to the same number of cells in different cell lines. 
In this way, the results obtained were not due to the number of treated cell, but simply because 
of the efficacy of compound 1. Consequently, the different cell lines were collected at a 
different time, N2a 5 days post seeding, while GT1 8 days post seeding, since it is known that 
the doubling time in N2a is faster than in GT1 cells.  
Even if all the controls are normalized to 100%, it is normal that in the untreated PK-digested 
samples (upper square in Figure 11 A) the amount of PrPSc is not the same, this reflects the 
difference in PrPSc protein level in different cell lines. 
The cell viability of compound 1 was assessed also on N2a-22L, GT1-RML and GT1-22L 
cells. The compound resulted not to be toxic at 4 µM also on these cells (data not shown). 
 
 
3.4 Understanding the mechanism of action of compound 1 
 
As already mentioned in the introduction, there are several possible mechanisms of action for 
a compound with anti-prion activity. Small molecules can block the prion replication using two 
different strategies: in the direct one, the compound induces the stabilization of the PrPC or the 
destabilization of the PrPSc, blocking the prion replication; in the indirect one, the molecule can 
act on some other protein involved in the prion replication or in the increase of PrPSc 
degradation. 
In the next experiment we tried to understand which mechanism is used by compound 1 to 
promote the strong reduction of prions in the cells. 
 
 
3.4.1 Treatment with ammonium chloride demonstrates the non-involvement of lysosome 
degradation pathway in the mechanism of action of compound 1 
 
Ammonium chloride (NH4Cl) is a salt highly soluble in water. In literature, there are several 
publications that assess the ability of NH4Cl to inhibit the lysosomal degradation and the 
phagosomes-lysosomes fusion [253, 254].  
The reduction of the level of PrPSc observed in the WBs of cell lysates, after the treatment with 
compound 1 (see for example in Figure 10 B), could be due to an increase of the physiological 
degradation activity of lysosomes promoted by compound 1. To figure out if the mechanism of  
 
__________________________________________________________________________ 
 
70 
 
 
 
 
Condition −PK +PK 
Ctrl 100 100 
NH4Cl 126.9 ± 4.1 131.5 ± 9.9 
1 47.1 ± 8.3 11.2 ± 5.1 
NH4Cl + 1 39.8 ± 4.6 9.4 ± 6.4 
 
Figure 12. The mechanism of action of compound 1 does not affect the lysosome degradation. (A) WBs of 
N2a-RML cell lysates in control condition, treatment with either 20 mM of NH4Cl or 4 µM of compound 1, and 
with both 20 mM of NH4Cl and 4 µM of compound 1. In the upper square the PrP signal after PK digestion is 
represented, in the middle the samples without the PK digestion (total PrP) and in the bottom the house-keeping 
protein, actin. (B) Quantification of the three independent experiments. The values under –PK and +PK point the 
percentage of the level of the total amount of PrP (–PK) and of PrPSc (+PK) normalized on the control (100%). 
The values after ± are the standard deviations (SD) 
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action of compound 1 involves the degradation of the PrPSc, N2a-RML cells were treated 
with 20 mM of NH4Cl in combination with compound 1. Untreated cells (neither with 
compound 1 nor NH4Cl) were used as control, then cells treated just with compound 1 (4 µM) 
or NH4Cl (20 mM) and cells treated with both compound 1 and NH4Cl. 
In Figure 12, results of these treatments on the cells are shown. In the samples treated just 
with 20 mM of NH4Cl, the level of PrPSc is 30% higher than in the untreated control. This 
result is probably due to the inhibition of the lysosome degradation by NH4Cl, that induces a 
slowdown of cell clearance pathways and so an increase of misfolded proteins, that cannot be 
cleared as usual. We expected that in the cells treated with both compound 1 and NH4Cl the 
level of PrPSc would be higher than in the samples treated just with compound 1, if the 
compound activity promoted an increase in the lysosome degradation. However, we observed 
that in the cells treated just with compound 1 and with both compound 1 and NH4Cl, the level 
of PrPSc was almost the same: 11.4% and 9.4%, respectively. A similar pattern observed in PK 
treated samples was present in the samples untreated with PK, even if less prominent.  
After these experiments, we concluded that the lysosomal degradation pathway is not 
involved in the compound 1 mechanism of action in the decrease of PrPSc. The next hypothesis 
was that compound 1 could affect the prion replication stabilizing PrPC or destabilizing the 
PrPSc.  
 
 
3.4.2 Effect of compound 1 on cellular prion protein in uninfected cells 
 
As previously mentioned in the introduction, according to the protein-only hypothesis, the 
prion replication is the molecular event that allows the self-propagation of prions through the 
conversion of the PrPC to PrPSc.  
The NH4Cl treatment revealed that the mechanism of action of compound 1 does not involve 
the lysosomal degradation pathways. If it is not the degradation, we speculated that another 
possibility could be blocking the prion replication. To inhibit the prion conversion, compound 1 
should bind the cellular prion protein or the scrapie PrP. In order to check if compound 1 binds 
PrPC and affects its protein level, we decided to treat uninfected N2a and GT1cells for 4 days at 
0.1, 1 and 10 µM of concentration, that were already tested for the cell viability on the same 
cells, using the MTT assay (Table 10). The mock control was used to control a possible 
influence of the vehicle solution (DMSO-EtOH) on the treatment.  
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Concentration (µM) N2a GT1 
Ctrl 100 100 
Mock 95.3 ± 2.1 103.2 ± .4.8 
0.1 93.6 ± 1.5 96.9 ± 2.9 
1. 97.3 ± 4.9 91.4 ± 6.3 
10 90.5 ± 8.5 97.4 ±9.2 
 
Table 11. Cell viability of compound 1 on N2a and GT1 by MTT assay. Here, the results of MTT assay of 
three independent experiments on Na and GT1 are represented. The values under N2a or GT1 are the percentage 
(%) of the viable cells in the control condition (untreated sample) and after the treatment with vehicle (Mock), 0.1, 
1 and 10 µM of compound 1. 
 
 
 
Figure 13. Western blot of compound 1 treatment on N2a (A) and GT1 (B) cell lines. Two representative 
WBs of the N2a (A) and GT1 (B) cell lysates after treatment with compound 1 at 0.1, 1 and 10 µM of 
concentration. The Ctrl corresponds to cells without any kind of treatment, while the Mock is the sample treated 
with the vehicle solution, a mix of DMSO and EtOH in a ratio 1:10. 
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Once it was shown that the compound 1 was not toxic for the uninfected N2a and GT1, we 
performed a WB to check if the level of the cellular prion protein in cell lysates of treated 
samples is affected. In Figure 13 the WBs of the treatment on N2a (A) and GT1 (B) are 
represented. Neither in N2a nor in GT1 the three concentrations of compound 1 change or 
affect the PrPC level.  
After these experiments, we concluded that compound 1 is not able to influence the level of 
PrPC, however, its ability to bind the cellular prion protein should not be excluded. 
 
 
3.4.3 Compound 1 does not affect the PrPC localization from the cell membrane 
 
The treatment of N2a and GT1 with compound 1 for 4 days revealed that it is not able to 
affect the level of the cellular prion protein. It is still necessary to understand whether the 
compound 1 binds PrPC. 
In 2017, as already mentioned in the introduction, Stincardini et al. demonstrated that the 
anti-prion activity of an antipsychotic, Chlorpromazine (CPZ), is not due to its binding to the 
PrPC. Indeed, through surface plasmon resonance (SPR) and dynamic mass redistribution 
(DMR), they estimated that the affinity of CPZ to PrPC is in a high micromolar range (KD=421 
µM), while the active concentration on infected cells is 100 times lower. This would mean that 
it is not possible that the mechanism of action of CPZ involves its binding to PrPC. Knowing 
that the antipsychotic effect of CPZ involves the clathrin-mediated endocytosis (CME) and that 
CME allows the recycling of PrPC from the plasma membrane, they assessed if the CPZ 
promotes a relocalization of the PrPC from the cell surface to the intracellular 
compartments[234]. 
CPZ and compound 1 are both phenothiazine molecules because they possess the 
phenothiazine moiety. For this reason, the following experiments were conducted to test if the 
mechanism of action of compound 1 involves a redistribution of PrPC. 
An immunofluorescence surface staining, without the cell permeabilization, was performed 
using N2a cells, treated with compound 1 at two different concentrations: 0.4 and 4 µM. PrPC is 
marked in green, while the DAPI dye in blue is used to visualize the nucleus. This staining was 
used to see if the level of the cellular PrP present on the cell surface is affected by treatment 
with compound 1. We expected that if compound 1 can promote a relocalization of PrPC as 
CPZ, the samples treated with the molecule at 0.4 µM, but especially at 4 µM, would exhibit a 
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decrease in the level of PrPC stained in respect to the untreated and the mock controls. On the 
contrary, we noticed that treated samples had the same pattern staining of the controls. 
This experiment allowed us to conclude that anti-prion activity of compound 1 does not 
implicate a PrPC redistribution from the cell surface to the intracellular compartments, as is the 
case for CPZ and other phenothiazine compounds. 
 
 
 
Figure 14. Surface immunofluorescent staining on N2a cells treated with compound 1. As for the other 
experiments, N2a cells were treated with compound 1 for 4 days. Before the staining the cells were incubated one 
day in a 24-well plate on the coverslip. Two different concentration of compound 1 were used: 0.4 µM and 4 µM. 
PrPC present on the surface is labeled in green, and in blue the nucleus. 
 
 
3.4.4 Activity of Compound 1 in the prion in vitro conversion  
 
After the last-mentioned experiments, we concluded that the mechanism of action of 
compound 1 does not involve the clearance of PrPSc by the activation or increase of lysosomal 
degradation activity. Compound 1 does not change the level of the cellular PrP and the 
treatment with it on uninfected N2a cells does not affect the redistribution of the PrPC from the 
plasma membrane to intracellular compartments. The experiments conducted so far were not 
able to answer the question if anti-prion activity of the molecule is due to its binding to the 
cellular PrP, or if this binding is decreasing the PrPC available for the PrPSc conversion leading 
to a reduction in the PK-resistant PrPSc, visible in the western blots. 
In order to have a better comprehension of the mechanism of action of compound 1, we 
checked if it is actually able to bind the cellular prion protein. In literature, several techniques 
are shown to be able to assess molecule-protein interactions, such as the isothermal titration 
calorimetry (ITC) [255], that can determine the thermodynamic parameters of interactions of 
small molecules to larger macromolecules in solution; the surface plasmon resonance (SPR) 
[256], an optical technique able to measure changes in the refractive index caused by 
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interactions between a mobile molecule and a molecule immobilized on a thin metal film; the 
bio-layer interferometry (BLI) [257], another optical technique that uses a biological layer, 
instead of a metal film to immobilize the molecule. 
We tried to use the SPR to check a hypothetical binding between compound 1 and the PrPC 
and eventually calculate the dissociation constant (KD) to assess if the anti-prion activity of 
compound 1 is caused by its binding with the PrPC. Unfortunately, we had many problems with 
the solution in which the compound was dissolved, consisting of EtOH and DMSO. For this 
reason, we tried to avoid the use of SPR and we designed a new protocol to evaluate the 
possible binding between compound 1 and PrPC, that we named “competition assay”. 
In this assay, PrP (23-231) and compound 1 were mixed in different ratios and incubated at 
37 °C with constant shaking at 350 rpm for 30 minutes. 
The ratios used are shown below: 
 
• PrP : compound 1 = 1:1 = 1µM : 1µM 
• PrP : compound 1 = 2:1 = 2µM : 1µM 
• PrP : compound 1 = 1:2 = 0.5 µM : 1µM 
• PrP : compound 1 = 1:5 = 0.2 µM : 1µM 
 
After 30 minutes of shaking, the mix and compound 1 alone (at the same concentration of 1 
µM) were centrifuged several times at 2000 rpm in Nanosep centrifugal device (Merk) with 
Omega membrane 3 kDa to pass the whole solution through. The centrifugations should not be 
higher than 1000 rpm to avoid the membrane breakdown. These tubes are permeable for 
compound 1 (416.93 Da) but not for the PrP (25 kDa) and the hypothetical PrP-compound 1 
complex (Figure 15). Regarding the concentration, we have chosen 1 µM instead of 4 µM, so 
that the concentration of PrP would not be too high. 
After several centrifugations, the solution above the membrane contains the molecule with a 
molecular weight higher than 3 kDa, so it should either be consisted of PrP alone or the PrP-
compound 1 complex if the binding has occurred. Meaning that the solution present in the 
tube’s bottom should contain molecules with a molecular weight lower than 3 kDa, such as the 
compound 1.  
All the solutions were then analyzed using two different approaches: with WB where they 
were added to the N2a-RML cells and in the RTQuIC where they were loaded into a 96-well 
plate. If the binding between PrP and compound 1 would occur, a decrease of PK-resistant 
PrPSc in the WB and inhibition of the prion aggregation in RTQuIC are expected.  
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3.4.4.1 Competition assay on N2a-RML cells  
Then, the solution from the bottom of the tube after the centrifugation, which should contain 
just the compound 1, was added to the N2a-RML cells as a normal treatment for 4 days.  
As a negative control, we used cells treated just with the vehicle. The cells incubated with 1 
µM of compound 1 without the centrifugation in the Nanosep centrifugal device and the N2a-
RML treated with 1 µM of compound 1 after the use of Nanosep tubes were utilized as positive 
controls. 
 
 
 
Figure 15. A representation of the competition assay. Different combinations of PrP and compound 1 were 
incubated for 30 minutes at 350 rpm at 37 °C. After this incubation, the mixes were moved from a normal 
Eppendorf tube into a Nanosep centrifugal device, which contains a membrane permeable to the molecules with a 
molecular weight lower than 3 kDa. Several centrifugations at ~1000 rpm allowed the molecules with MW < 3 
kDa to cross the membrane and reach the tube’s bottom. This solution was used as a treatment and incubated with 
the N2a-RML cells for 4 days or loaded to a 96-well plate to perform a RTQuIC for 3 days. 
 
After 4 days of treatment, the cells were detached from the Petri’s dish and centrifuged. The 
supernatant was thrown away and the pellet was lysed. WB analysis was used to detect the 
level of PK-resistant PrPSc after the treatment. The experiments were repeated three times, so 
we collected independently three times the cell lysates after the treatment with the solution 
obtained after the use of the Nanosep device and for each collection we performed a WB. In 
figure 16 A, it is possible to observe one representative WB obtained. We noticed immediately 
Mixes:
• FLMoPrP : 1 = 1:1 = 1µM : 1µM
• FLMoPrP : 1 = 2:1 = 2µM : 1µM
• FLMoPrP : 1 = 1:2 = 0.5 µM : 1µM
• FLMoPrP : 1 = 1:5 = 0.2 µM : 1µM
30 minutes, 350 rpm, 37 °C
Nanosep
centrifugal device
+ 
mix
After some 
centrifugations 
at < 1000 rpm
After several 
centrifugations 
at < 1000 rpm
Molecules with MW > 3kDa
Molecules with MW < 3kDa
4 days 
3 days 
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that the treatment with compound 1 without the use of Nanosep tube and the treatment with the 
solution obtained after putting compound 1 alone in the tube caused the same effect on the 
N2a-RML. In both cases, it is possible to see a strong and a very similar reduction of the PrPSc. 
This result confirmed the functionality of the Nanosep device, because it means that compound 
1 alone is able to cross the membrane, indeed 3kDa > 416.93Da (1 MW). Once we concluded 
this, we checked what happened when the PrP and compound 1 are put in the Nanosep tubes 
after a pre-incubation at 37 °C with shaking. As it is possible to see in figure 16 A, when the 
ratio is 2 moles of PrP and 1 mole of compound 1 or 1 mole of PrP and 1 of 1, the level of PK-
resistant PrPSc is not affected by a strong reduction as it happened after the addition of 
compound 1 alone. 
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B 
Condition −PK +PK 
Ctrl 100 100 
1 48.8 ± 4.5 25.2 ± 7.8 
1 (N) 51.7 ± 6.7 22.6 ± 9.5 
2:1 (N) 114.4 ± 7.1 108.2 ± 3.8 
1:1 (N) 117.6 ± 7.3 90.1 ± 2.9 
1:2 (N) 98.4 ± 5.2 65.7 ± 5.7 
5:1 (N) 41.0 ± 4.8 13.6 ± 9.0 
 
	
	
	
	
	
C 
 
 
Figure 16. Competition assay in N2a-RML cell line. (A) Representative WB of the cell lysates of N2a-RML 
treated in different conditions. The first line corresponds to the untreated sample, then in order: sample incubated 
with 1 µM of compound 1, samples treated with the solution obtained from the bottom part of Nanosep device 
after several centrifugations of compound 1 alone, cells incubated with the solution obtained from the bottom part 
of Nanosep device after several centrifugations of a pre-incubated PrP and compound 1 in ratios 2:1, 1:1, 1:2 and 
1:5. In the upper part the cell lysates are represented after the PK-digestion (PrPSc), in the bottom the samples 
without the PK treatment. (B) The table that shows the quantification of the three-independent experiment 
performed. The values under −PK represent the normalization of the total PrP on the actin, the values under +PK 
represent the PrPSc on the total PrP. The values after ± are the standard deviations (SD). (C) Histogram of the 
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values present in the figure 16 B. The total PrP (−PK) is in dark blue, the PrPSc is in light blue (+PK). The values 
are normalized to 100%.  
This mean that when the two molecules are incubated in the ratios 2:1 and 1:1, there is a 
binding that does not allow the compound 1 to cross the membrane and it remains attached to 
the protein, otherwise the results would have the same of those in line 1 and 1 (N), since the 
compound 1 crosses the 3kDa membrane of the Nanosep tubes. After the quantification, this 
result is even more evident. Treatment directly with compound 1 or after the use of Nanosep 
device produced a PrPSc inhibition around 30%, while in the 2:1(N) and 1:1(N) did not cause 
any or a strong inhibition, the values are around 100% and 90% (figure 16 B and C). When the 
mixes were prepared in a ratio 1:2, 1 mole of PrP and 2 moles of compound 1, the level of 
resistant-PK PrPSc decrease to 65%, demonstrating that a part of compound 1 was linked to the 
PrP and the other crossed the Nanosep membrane and affected the level of PrPSc. We also used 
a ratio in which the concentration of compound 1 is 5 times higher than the PrP (1:5). The 
strong inhibition of PrPSc from 100% to 23.6%, using the ratio 1:5, could be explained again 
through the binding between PrP and compound 1. In this case the level of PrPSc is the same as 
in the samples treated just with compound 1, probably because compound 1 is in a large excess 
causing the majority of it to cross the 3 kDa membrane. 
All the results obtained using the different ratios and treating the cells with the solution 
present in the Nanosep device’s bottom, led us to believe that the compound 1 is actually able 
to bind the PrP.  
The level of total PrP followed the same trend of PrPSc, even if the decrease is less evident. 
This demonstrates that compound 1 is able to affect just the PrPSc level, although it binds the 
PrPC. 
 
3.4.4.2 Competition assay using RTQuIC 
RTQuIC analysis was performed using the same solutions obtained after the competition 
assay, such as in WBs. We decided to check if there were differences in the results using these 
two different approaches. Both of them have advantages and disadvantages, in the WBs it is 
possible to see the effect of the treatment on living cells, but it is possible to detect only the 
presence of PK-resistant PrPSc and not in low quantity; while in the RTQuIC it is not possible 
to consider all the other potential factors that are present in cells and that can trigger the 
spreading of PrPSc, however, it is able to detect very low amounts of prions. 
In the RTQuIC assay, the PrP (23-231) alone was used as a negative control, because it is 
known that this protein is not able to aggregate in the absence of a seed [258]. Instead, the 
positive control consists of PrP with a PrPSc seed. For this purpose, a confluent 10 cm2 plate of 
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N2a-RML cells was collected in 50 µl of PBS and then sonicated. The sonicated proteins, 
present in the sample, were quantified. We tested two different amounts, 1 µg and 10 µg, and 
tested which one gave the best result in terms of seeding activity and reproducibility. Figure 17 
shows the curves using the two different seeds. 
 
 
 
Figure 17. Aggregation curves of PrP (23-231) using 1 µg or 10 µg of the seed. Three independent RTQuIC 
experiments, each one represented by a specific color. (A) The aggregation is promoted by 1 µg of the seed. (B) 
The aggregation of PrP is allowed by 10 µg of the seed. 
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Figure 18. Aggregation curves of PrP after the treatments with the solution obtained with the competition 
assay. In each plot, the three independent experiments are represented with orange, gray and blue lines. RtQuIC of 
(A) only PrP (23-231), (B) PrP with 1 µg of the seed, (C) the solution obtained after the pre-incubation and 
centrifugation in the Nanosep device of the mix consisting PrP and compound 1 in a ratio 2:1, (D) 1:1 and (E) 1:5. 
The mock control of the condition (C), (D) and (E) are represented in the (F), (G) and (H). 
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Using only the seed at 1 µg, we obtained an aggregation curve, for this reason we decided to 
use 1 µg of seed for the later experiments. 
We have set up an RTQuIC protocol, by which the negative control consists of only PrP, that 
did not show a curve aggregation (Figure 18 A) and the positive control that has a reproducible 
curve aggregation after about 1050 min (17,5 hours) (Figure 18 B). This protocol was used to 
check whether the RTQuIC assay could confirm the results obtained in WB analysis.  
As before, the same competition assay procedure was performed, but instead of cell 
treatment, the solutions were added to the 96 well plate. 
The experiments confirmed what we saw in the WBs, the solution obtained from the pre-
incubation of PrP:compound 1=2:1 after several centrifugations using the Nanosep device 
contains prions. Indeed, in figure 18 C it is possible to observe that the aggregation curves have 
the same ThT fluorescence, around 6000 AU, and the lag phase (1050 min) as the positive 
control. Also, in the WBs analysis, the level of PrPSc in this condition was the same of the 
untreated control. So, these two different assays support our hypothesis that compound 1 binds 
PrP and so it is not able to cross the 3kDa membrane present on the Nanosep device and to 
inhibit PrPSc and its aggregation. When the ratio used is PrP:compound 1=1:1, the aggregation 
curves of the three independent experiments are not comparable (figure 18 D). In two 
experiments (blue and gray lines), the prion aggregation started later than in the positive 
control, around 1890 (31,5 hours) and the ThT fluorescence is less intense (4500 AU). In the 
other experiment (orange line) the aggregation started normally, but the fluorescence had an 
uncommon increase after 2100 min (30 hours), so we decided to not consider it for further 
analysis. Also, in this case the RTQuIC assay confirmed the WBs results. The increase of the 
lag phase and the decrease of ThT fluorescence can mean a lower presence of prions and this 
could correspond to the results of the WB, where after the treatment with the solution obtained 
from PrP:compound 1=1:1 mix, the level of PrPSc started to decrease (figure 16 B and C). 
These results mean that at the ratio 1:1, almost all molecules of compound 1 bind the PrP, 
causing just a little inhibition of prions aggregation. In figure 18 E, results from the RTQuIC of 
PrP treated with the solution obtained after the pre-incubation and centrifugation in the 
Nanosep tubes of the mix PrP:compound 1 = 1:5 is represented. The delayed aggregation 
curves (starting around 50 hours) and the low ThT fluorescence (4000 AU) could be due to a 
low presence of prions, that corresponds exactly to the strong inhibition of the PK-resistant 
PrPSc seen in WB. This again could mean that even if compound 1 binds PrP it is in a large 
excess and can cross the 3kDa membrane. So, when the solution in the bottom of the Nanosep 
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tube is added to the 96-well plate, there is enough of compound 1 which is able to bind the PrPC 
and partially inhibit the aggregation. 
We also checked if the EtOH-DMSO reagents, in which the compound 1 is dissolved, affect 
the reaction. In figure 18 F, G and H the aggregation curves of MoPrP treated with the same 
amount of EtOH-DMSO present in the corresponding treatments with compound 1 are 
represented. It is possible to notice that the lag phase and the ThT fluorescence are the same of 
the positive control (PrP+seed), confirming that the vehicle does not influence the result. 
 
Taking together the WBs and RTQuIC experiments, we conclude that the compound 1 is able 
to bind the PrP (23-231) and so the cellular prion protein. 
 
 
3.5 Effect of chronic treatment with compound 1 on N2a-RML cell line 
 
In literature, there are many papers that show the ability of different small molecules to 
decrease the level of mouse PrPSc and/or inhibit the prion aggregation [228, 259-262]. 
Unfortounately, there is still no cure for TSEs. The cause of failure in finding a therapy can be 
various, such as the inability to cross the BBB, inefficacy in complex model and other many 
factors that are so far unknown. Another possible cause of the common failure of anti-prion 
compounds is the drug-prion resistance that can be developed after a continuous chronic 
treatment and results in a prion strain selection, such as it happened for the Quinacrine 
treatment in prion-inoculated MDR0/0 mice [214].   
In order to assess if N2a-RML cells treated with compound 1 can be walking into a strain 
resistant and to check if it is able to cure the N2a-RML cells, a chronic treatment was 
performed. We treated N2a-RML cells with 4 µM of compound 1 for 5 passages, that 
correspond to 20 days of treatment. After this period, the incubation with compound 1 was 
stopped and the cells were maintained in culture without any treatment for other 5 passages to 
check if this kind of treatment with compound 1 for 20 days is able to clear completely cells 
from prions (figure 19).  
After 40 days, 10 passages of N2a-RML cells were obtained. For each passage and each 
experiment, we had 2 Petri dishes, one to continue the experiment, one to collect the cells at 
each specific step. The cells were detached from the 10 cm2 Petri dishes, centrifuged for 5 
minutes at 1200 rpm and the pellet was collected at -80 °C. This experiment was performed 3 
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times and each time in double, because we assessed the activity of compound 1 in chronic 
treatment using both WB analysis and RTQuIC assay. 
 
 
 
 
 
Figure 19. Chronic treatment with compound 1 on N2a-RML cells. (A) Schematic representation of the 
chronic treatment with compound 1. N2a-RML cells were incubated with 4 µM of compound 1 for 5 passages, 
after this period the treatment was stopped, and the cells were passaged for others 5 times. (B) Representative WB 
of N2a-RML cell lysates. The upper part corresponds to the PK-resistant PrPSc detected using the W226 primary 
antibody. The same was used in the cell lysates not subjected to PK-digestion. In the bottom part the actin is 
represented, detected using the anti b-actin antibody. 
 
For the WBs, the samples were prepared, as mentioned above, by lysing the pellets in the 
proper buffer and then boiling in loading buffer. We used the lysates of uninfected N2a cells 
and the N2a-RML before the treatment (#0) as controls. So, looking at the WB, it is 
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immediately possible to notice that the PrPSc in N2a cells is absent, as we expected. Indeed, 
after PK-digestion no signal was detected. At #0, N2a-RML cells showed the typical pattern of 
the RML prion strains: the three bands with the mono-glycosylated one more evident. But 
immediately after the first passage of the 4 µM treatment with compound 1, PK-resistant PrPSc 
is almost absent. In the following passages (from #2 to #10) the PrPSc is not even detectable. It 
is very important to focus the attention on the fact that from the #6 to #10 the treatment with 4 
µM of compound 1 is stopped. So, the absence of PrPSc signal in these passages demonstrates 
that the compound 1 is able to “cure” the N2a-RML cells from prions and that it does not 
undergo a drug-prion resistance. The level of total PrP was evaluated, observing the samples 
not treated with PK-digestion. Also, here the uninfected N2a lysate was used as a control. The 
total PrP does not reflect the results obtained for the PrPSc, because in this case the #0 and #1 
have the exactly same pattern, while in the PK-treated samples the level of PrP was strongly 
reduced already in the #1. Conversely, the total PrP signal from #2 until #10 is unchanged, but 
is exactly the same of the PrPC signal from the uninfected N2a cells (line 1). Thus, from the 
WB it seems that in the samples of N2a-RML with or without the treatment with compound 1 
since the #2 the only prion protein present is the cellular prion protein.  
The same samples were checked also in the RTQuIC assay. After cell collection, the pellet 
was dissolved in 50 µl of PBS and then sonicated. The sonicated proteins were quantified, as 
already mentioned in the previous chapter, and 1 µg of them was used as seed. In figure 20, it is 
possible to observe the RTQuIC experiments that we performed with the same type of samples 
used for WBs, to compare the two different approaches. In the control (figure 20 A), without 
treatment with 4 µM of compound 1, prion aggregation started after 1050 minutes (17,5 hours). 
The same result was obtained in the #1, where the ThT fluorescence intensity and the lag phase 
were identical as in #0. At #1 the aggregation curve obtained in RTQuIC (figure 20 B) reflects 
the WB result without the digestion with the proteinase K (figure 19 B), but not the result of the 
PK-digested sample.  
While in WB, at #2, in both PK and non-PK treated samples, the PrPSc seemed completely 
cleared, in RTQuIC experiments, the lag phase was a little elongated (1260 minutes, 21 hours) 
and the ThT fluorescence was decreased, for some peaks to 7000 AU in #0 and #1 to 5000 AU 
in #2 (figure 20 C). The same kind of incongruence was noticed in #3, because in the WB  
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Figure 20. Aggregation curves of PrP after the addition of a seed, obtained from a chronic treatment on 
N2a-RML cells. In each plot, the three independent experiments are represented with the orange, gray and blue 
lines. (A)  RTQuIC performed with 0.2 mg of PrP and using 1 µg of sonicated protein from N2a-RML cells. (B) 
RTQuIC of PrP and using 1 µg of sonicated protein from N2a-RML cells after one treatment with compound 1 at 
4µM. In (C) the seed derived from a second passage of the treatment with 1, in (D) third passage, in (E) fourth, in 
(F) fifth, in (G) sixth, in (H) seventh, in (I) eighth, in (L) nineth and in (M) the tenth. The average of the three 
independent experiments of all conditions (N). 
 
the PrPSc signal is completely absent, while in the RTQuIC the presence of prions is evident by 
the aggregation curve (figure 20 D). At passage #4, in two out of three experiments, the PrP is 
not able to aggregate, just one sample started the aggregation around 45 hours (2730 minutes) 
(figure 20 E). We did not consider it as a technical problem, because all the 4 wells of that 
experiment aggregate at the same time and with the same intensity, rather we believed that after 
4 passages of treatment with compound 1, the prions in almost all the experiment were cleared 
but it is possible that sometimes they were not completely eliminated. But the fifth treatment 
with compound 1 is incontrovertibly able to remove all the prions present in the N2a-RML 
cells and the proof is the absence of an aggregation curve in all the passages after the #5 (figure 
20 F-M). 
The fact that even after the #5, that corresponds to the treatment interruption, none of the 
samples demonstrated to have prions using both the RTQuIC assay and WB analysis, 
confirmed the ability of compound 1 at 4 µM of concentration for 5 times to cure the ScN2a 
from the RML prion strain.  
In figure 20 N, the average of the three independent experiments performed, shows the 
progressive decrease in prion concentration from #0 to #10. This reduction is mainly 
characterized with a decrease in the ThT fluorescence, rather than in an increase in the lag 
phase. 
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CHAPTER IV 
 
 
 
 
DISCUSSION 
 
 
Prion diseases or TSEs are triggered by the aberrant misfolding of the cellular prion protein. 
The conformational change and replication of the PrPC to its pathological isoform (PrPSc) are 
followed by aggregation and cell-spreading in the nervous system, that lead to a fatal 
neurodegeneration. So far, no therapies against TSEs have been identified. Indeed, the 
scientific community collected just failures and frustration trying to cure or at least modify the 
course of these disorders. The most common strategy used is the design and screening of small 
molecules. Many of them were already tested in human clinical trials, but none gave the 
expected result, probably because the development of anti-prion drugs and the understanding of 
their mechanism of action are very difficult and challenging tasks. 
In collaboration with the Jülich Institute, a quantitative structure-activity relationship model 
(QSAR) has been developed and by using it a virtual screening of some purchasable 
compounds has been performed. With the help of the QSAR model, we obtained a library of 10 
molecules. The library was then tested in vitro study using N2a mouse cell lines chronically 
infected with prions to assess their anti-prion activity. Compound 1 emerged as the most 
promising molecule, so we tried to assess its mechanism of action. 
In the present section, the results that led to the selection of the compound 1 and to the 
understanding of its mechanism of action will be discussed. 
 
 
4.1 Identification of compound 1 as anti-prion agent 
 
The in silico screening has been performed through the design of a QSAR model. This model 
tries to understand the possible relationship that occurs between the activity of a compound and 
its chemical structure. In order to build a QSAR model, our collaborators used a library of 
molecules known to have an anti-prion activity on N2a RML cell line [209, 232, 238, 260, 263-
269]. The QSAR model is a mathematical equation able to measure the predicted biological 
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activity of a molecule, in this case the IC50 against the PrPSc. With the aim of identification and 
selection of new compounds with anti-prion activity, the QSAR model was used to perform a 
virtual screening of the ZINC database, that contains around 35 million of purchasable, FDA 
approved molecules. From the compounds obtained with this screening, we selected the ones 
with a pIC50 in the nanomolar range.  
The first assessment of the anti-prion activity of the selected library was performed on N2a 
mouse cells chronically infected with RML prion strain at 1 µM of concentration. In this part of 
the screening, we tried just to identify the molecules able to reduce the level of PrPSc that is 
actually the desired physiological effect, without knowing the mechanism of action. At the 
beginning, we decided to treat the cells with only one concentration (1µM) of each compound, 
in order to discard all the molecules that did not reach the intended result. 1 µM was the 
concentration chosen, because from the QSAR model the molecules were predicted an IC50 in 
the nanomolar range. The cell viability of N2a-RML cells has been tested before to discard any 
toxic compounds. But none of the compounds showed to have a toxic profile.  
The treatments with each compound on N2a-RML cell reveled the strong activity at 1 µM of 
the compound 1. Indeed, it is able to induce a reduction of the PK-resistant PrPSc of more than 
65% in N2a-RML cells. Then, we measured, on the same cell line, the IC50 of compound 1, that 
resulted to be 0.42 µM. Although there is a substantial difference between the pIC50 calculated 
(54.9 nM, table 6) and the IC50 calculated on the cells, the strong anti-prion activity of this 
compound is anyway confirmed. The ability of compound 1 to clear the PrPSc was confirmed 
also in other cell lines that we have in our laboratory, the N2a-22L, GT1-RML and GT1-22L. 
The first part of the in vitro screening showed also that compound 1 was the most effective 
anti-prion agent in the library, as previously evaluated by the QSAR model.  
Looking at the structure of this molecule, we noticed that it consists of two main moieties a 
phenothiazine and a 7-chloro-quinoline fragment, bound by a hydrazine linker (figure 21). We 
can consider compound 1 as a bivalent ligand with an appropriate linker. The two moieties are 
very well-known prion recognition motif. In 2001 Korth et al. tested the same phenothiazine 
moiety and it was already shown to be an anti-prion agent in N2a-RML [209]. They noticed 
that phenothiazine was not able to inhibit PrPSc or to strongly decrease its level of PrPSc, except 
at 10 µM. So, we concluded that the effect we saw in compound 1 is not only due to the 
presence of the phenothiazine moiety.  
 The 7 chloro-quinoline fragment is defined as a prion recognition motif, because several 
quinoline derivatives were tested as potential anti-prion drugs with excellent results. 
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Figure 21. Structure of Compound 1. Compound 1 consists of a phenothiazine, 7-chloro-quinoline fragment and 
a hydrazone linker. The two moieties are prion recognition structure. Several studies aimed their anti-prion 
activity. Therefore, the phenothiazine fragment was screened by Korth et al. in 2001. 
 
On the basis of these findings, Korth's group studied the structure-activity relationship of a 
series of quinoline derivatives as potential antimalarial and anti-prion drugs. 
It has been demonstrated that there is a possible overlap between some molecular targets of 
anti-prion and anti-malarial compounds, because they are able to inhibit at the same nanomolar 
concentration both scrapie-infected cells and P. falciparum growth [264]. As in malarial 
studies, also bis-quinolines were tested as inhibitors of PrPSc accumulation in cell cultures. 
Generally, the bis-quinolines are more effective than normal ones to inhibit the fibril formation 
in vitro, but unfortunately, they show lower efficiency in in vivo experiments. Fukuuchi et al. 
demonstrated that the bis-quinolines tested inhibit PrP biosynthesis and PrP transition to the 
cell surface and also decrease the amount of substrate available for conversion to PrPSc [270].  
So, we conclude that the strong efficacy of compound 1 to inhibit the prion formation and to 
decrease the PrPSc from prion infected cells is due to a synergistic activity of the two moieties 
and the rigid hydrazone linker between them [271]. Indeed, these three structural elements are 
very well-known to positively affect the prion inhibition and clearance. 
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4.2 Understanding the mechanism of action of compound 1 
 
Although, as already mentioned, in literature a variety of small molecules tested in vitro 
screening against prion diseases are present, the majority of them have an unknown mechanism 
of action. For this reason, when these molecules failed in animal model or human clinical trials, 
it is very challenging for the scientific community to comprehend the causes of the failure.  
The activity of a compound in promoting the clearance of the PrPSc and inhibit the prion 
aggregation could be due to several reasons. The two main strategies that an anti-prion agent 
can adopt in order to obtain the wanted result are:  
 
• The activation of some pathways involved in the prion degradation  
• The blocking of the prion conversion 
 
To assess whether the mechanism of action of compound 1 was due to the activation of the 
lysosome degradation pathway, we treated the N2a-RML cells with 20 mM of NH4Cl in the 
presence or absence of 4 µM of compound 1. Indeed, it is known that the ammonium chloride 
is able to inhibit the lysosomal degradation and the phagosomes-lysosomes fusion [253, 254]. 
In the samples treated with just 20 mM of NH4Cl, the level of PrPSc was higher than in the 
untreated control. This result was caused by the inhibition of the lysosomes degradation by 
NH4Cl, that induces a slowdown of PrPSc clearance pathways and so an increase of misfolded 
proteins, that cannot be cleared as usual. If the compound 1 mechanism of action promotes an 
increase in the lysosomes degradation, the cells treated with both compound 1 and NH4Cl 
should have a higher level of PrPSc than the samples treated with just compound 1. But we 
observed that in the cells treated with just compound 1 and with both compound 1 and NH4Cl, 
the level of PrPSc was almost the same. So, after this experiment we concluded that compound 1 
does not affect the lysosome degradation pathways. 
Even if in the cells there are other pathways involved in the degradation of misfolded 
proteins, we decided to assess if the activity of compound 1 causes the blocking of the prion 
conversion. This blocking could happen in a direct mechanism by which the compound induces 
the stabilization of PrPC and/or the destabilization of PrPSc or by an indirect mechanism, by 
which the molecule interacts with other components of the prion replication. 
Starting from the fact that the proteins and the other molecules involved in the mechanism of 
prion conversion are not so well known, we decided to avoid the screening of the possible 
protein that can be a target of compound 1 and focus the attention the prion protein. 
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The structure of PrPSc is poorly defined [229] and it is very difficult at the same time to 
imagine a molecule able to bind the PrPSc and promote its degradation. So, we think that the 
most sensate approach for an anti-prion agent is to bind PrPC and consequently prevent binding 
with PrPSc and in that way, inhibit the prion conversion. On the cellular prion protein, there are 
some binding sites, where a molecule can stick and block the contact with the PrPSc avoiding 
the prion conversation and propagation.  
Recently it has been demonstrated that many compounds with a good anti-prion activity, 
designed to bind the cellular prion protein, exert their function through different mechanisms, 
rather than just linking to the PrPC. For example, Stincardini et al. in 2017 showed that the 
antidepressant Chlorpromazine, that was believed to bind the PrPC, actually causes a re-
localization of the cellular prion protein from the plasma membrane into intracellular 
compartments [234]. The chlorpromazine and compound 1 have a similar structure, because 
they share the phenothiazine moiety (Figure 22). In order to check if this moiety causes the re-
localization and to assess if compound 1 has the same behavior, we decided to perform an 
immunofluorescence assay on uninfected N2a cells labeling the cellular prion protein present 
on the cell membrane. As it is shown in the results, the treatment with compound 1 does not 
promote the redistribution of the PrPC. This demonstrates that the phenothiazine moiety is not 
involved in this mechanism. 
 
 
 
Figure 22. Structures of chlorpromazine and compound 1. These two molecules share the phenothiazine 
moiety as it is highlighted in the blue circle.  
 
 
To assess the possibility of a binding between compound 1 and PrP (23-231), we designed a 
protocol that we named competition assay. In this protocol, we used the PrP (23-231) to mimic 
the presence of the PrPC. The PrP (23-231) and compound 1 were pre-incubated in tubes in 
different ratios. The mixes were then centrifuged in the Nanosep device tubes that contain a 
membrane of 3 kDa. The solution obtained after the centrifugation was used as a treatment in 
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N2a-RML cells and in RTQuIC experiments. The results obtained using both techniques 
demonstrate the ability of compound 1 to bind the PrP (23-231). 
We also noticed, performing a chronic treatment, that the incubation with compound 1 at 4 
µM for 5 passages on N2a-RML cells is able to cure them from prions, because even after 
additional 5 passages no prions can be detected. This experiment demonstrated at the same time 
that, as it is already known from the literature, that the RTQuIC assay has a higher sensibility in 
the detection of prions than WB analysis. In the WBs the PrPSc was not visible anymore after 
the second passage, while in the RTQuIC there was a presence of prions until the 4th passage. 
 
In conclusion, in the present thesis we have shown a precise biological protocol for the 
identification of novel potential therapeutic anti-prion agent. We assessed the ability of the 
compound 1 to bind the cellular prion protein and so to inhibit the prion conversion.  
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APPENDIX I 
 
 
 
SUPPLEMENTARY RESULTS 
 
PROTEIN EXPRESSION AND PURIFICATION 
 
 
1. Prion proteins expression in LB medium. 
The MoPrP (23-231) was cloned into plasmid pET11a. The recombinant protein was 
produced in E. coli Rosetta2 cells in LB medium. 
Large scale protein expression was achieved using a 2 L bioreactor which allows an 
automated pH, stirrer, temperature and pO2 control. The characteristic fermentation plot of a E. 
coli BL21(DE3) culture grown in LB medium is presented in Figure 1 B. As we can see from 
the pO2 curve, bacteria consume oxygen intensively for about 6 hours after induction. The 
expression in bioreactor allows bacterial yield of 9-10 g/l of paste and a final OD600 nm of 7-8. 
On the basis of expression protocols already established in our laboratory, we confirmed that 
the PrP expression always results in the formation of insoluble inclusion bodies (Figure 1 C). 
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Figure 1: Large scale expression of WT MoPrP (23-231). 
(A) 10 L bioreactor station. (B) Fermentation plot of the 
protein of interest in M9 MM. pO2 is the curve of soluble 
oxygen in the medium. During the bacterial growth, it starts 
from 30-35% (exponential phase) until ~75% (plateau). The 
pH curve remains at physiological value thanks to the 
automated control with acidic and basic solutions. (C) 
Expression of MoPrP23-23o in E. coli Rosetta 2, T0: before 
induction, T16: 16 hours after induction, IB: inclusion 
bodies.  
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2. Protein purifications and refolding 
The main advantages of the expression of prion proteins as insoluble inclusion bodies are the 
high levels of expression and the possibility to easily purify extremely pure proteins after the 
first purification step. However, inclusion bodies need to be solubilized in strong denaturant 
agents (such as GndHCl or urea) before use. Therefore, the purification of the MoPrP(23-231) 
was achieved in non-native condition due to the presence of 2-6 M GndHCl in the buffers. 
Another aspect limiting our work with proteins expressed as inclusion bodies is the refolding 
process. This step always resulted in protein precipitations (approximately 50% of the total 
amount of refolded protein), which required additional re-solubilization steps with GndHCl of 
protein precipitates and refolding. 
 
 
 
 
 
 
 
 
Figure 2. Protein purifications. Size exclusion chromatography profile, and below and SDS-PAGE of 
MoPrP(23-231). 
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QSAR MODEL 
 
 
Recent structure deposits (PDB 4MA7, 4MA8) have revealed binding information of tricyclic 
ligands (Promazine and Chloropromazine) in complex with mouse PrP. Tricyclic derivatives 
are considered GN8 [125] fused ring derivatives. GN8 is believed to achieve its anti-prion 
activity by specific binding [125]. The binding site of Promazine derivatives in moPrP is in 
agreement to docking molecular dynamics NMR studies of GN8. Altogether, it seems that 
some prion recognition motifs (of GN8 derivatives and 2-3 fused ring analogs) specifically 
interact with the shallow cavity formed between β1,2 and α2. The particular importance of this 
region for mediating the PrPC-PrPSc conversion was later elegantly illustrated by the 
introduction of a new β0 (residues 118-122) from the HuPrP (23-231)·Nb484 crystal complex 
(PDB 4KML). Collectively, these studies provide a rationale for investigating the interactions 
between anti-prion compounds and the shallow cavity in the mechanism of PrPC-PrPSc 
conversion. We conducted a brief quantitative structure-activity relationship (QSAR) study to 
extract binding information from published data using statistical calculations. 
Based on the assumption that anti-prion compounds derived from GN8 share similar binding 
specificity, an anti-prion compound database has been curated from literature for QSAR study. 
This database contains ca. 200 compounds with known anti-prion activities (IC50) (A total of 14 
publications were used, See Table S1). We first subdivided this dataset into 5 datasets by the 
type of cell line and the incubation time of inhibitors (see Table S2). Next, for each of them we 
generated a QSAR model. Only the best model, across the five datasets, was considered and 
therefore presented here. This is the QSAR model based on the ScN2a dataset.  
Constitutional, Topological, Geometric, Electrostatic, Hydrophobic and Steric descriptors were 
generated, plus the drug-likeness (Lipinski’s rule of 5 [272]) were calculated by using PaDEL-
descriptor [272].  
Among those, five selected variables were identified as optimal dimension to develop the final 
model (see Methods for details). These are LogP, Molecular Weight (MW), No. of Sulfur 
atoms (Nsulfur), No. Tricyclic scaffold (Ntricyclic) and Molecular size (diameter, D).  
The best MLR model obtained with its statistical parameters is shown below:  
pIC50= 0.2344(0.066)LogP  -  0.0047(0.008)MW + 0.3597(0.1135)NSulfur + 
0.6237(0.2450)NTricyclic + 0.2278(0.0242)D + 2.6812  
n=38, R2=0.8028, R2adj=0.7720, s=0.3440, F=26.0602, Q2loo=0.7191, Q2lmo,30%=0.7056, 
R2- R2adj=0.0308 
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where n is the number of compounds of the training set, R2 is the coefficient of determination, 
R2adj is adjusted R2 based on the number of independent variables in the model (goodness-of-
fit statistic), s is standard error of estimate, F is variance ratio. R2 (the highest value is in 
correspondence with the good fitting of the model) should be compared with Q2loo (Leave One 
Out - for the highest values and comparable with R2, the model is robust), R2−Q2loo (a lower 
value is indicative of the model stability), Q2lmo (leave many out – if comparable with the 
values of R2 and Q2LOO the model is stable). 
As shown in the model equation, using only five predictors (molecular descriptors), around 
80% of the biological activity of the compounds can be predicted. R2adj of 0.7720, which is 
indicative of the convenience to add a new descriptor to the model, is comparable with R2; 
Therefore, we can say that no existing overfitting is in the model, as it presents a good fit with 
minimum number of descriptors. 
 
 
Figure 1. QSAR model obtained by QSARIN software on ScN2a 
The fitting and stability of the model were evaluated using internal validation procedures; first, 
we took into account the parameters of the cross-validation Leave-One-Out (loo). According to 
the obtained results, it is possible to affirm that the internal predictions are good since the 
variance explained in the prediction by loo (Q2loo = 0.7191) has a comparable value with R2 = 
0.8028.  
A stronger technique included in the QSARINS is Leaving-Many-Out (lmo), which was 
developed leaving out the 30% of the dataset to study the behavior of our model. This 
technique is very useful since in opposite to loo, where for each single disturbance of the data 
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the influence on the predictions might be weak; in lmo technique, each perturbation of data is 
significant. The model is considered stable because the R2 = 0.8028 and Q2lmo=0.7191 values 
are comparable.  
Virtual Screening 
With the aim of performing identification/selection of new compounds with anti-prion activity, 
the obtained model was used for the virtual screening of the ZINC database (35 million 
purchasable, http://zinc.docking.org FDA approved molecules). We first filtered the database 
only considering the ones similar to the chloroquine moiety. Around 5000 compounds were 
retrieved. Among those, only 2039 compounds respect the Lipinsky rule of 5 and 2029 of these 
were within the Applicability Domain of our proposed model. The predicted pIC50 is shown in 
Figure 2. The compounds with highest predicted pIC50 were tested in the experiments. 
 
 
Figure 2. Distribution of the predicted pIC50 among the 2029 compounds extracted from the ZINC database. 
Example of compounds with highest predicted pIC50 are highlighted in the red box. 
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APPENDIX II 
 
 
 
SUPPLEMENTARY MATERIALS AND METHODS 
 
Model generation. For the calculation of molecular descriptors, PaDEL-descriptor [Yap CW 
2011 J Comput Chem 32 1466 1474]   Molinspiration [www.molinspiration.com] were used.  
Given the great number of variables calculated, the data were subjected to a filtration process 
using the QSARINS software [237] and the descriptors that possessed more than 95% of 
constant values and had more than 90% correlation were eliminated. After that, only 33 
descriptors were considered in the selection process to develop the model.  
It would be ideal to use all combinations of available descriptors for the calculation of the 
models; however, the number of combinations is usually so great that it is impossible to 
calculate all models. Therefore, to reduce the model computation time, all combinations were 
preliminarily used with only a small number of descriptors per model, in order to explore all 
combinations of low dimension, using the all subset technique, and, later, a genetic 
algorithm (GA) method was applied to develop models based on a larger number of 
descriptors.  
The Multiple Linear Regression (MLR) is the process that we used to obtain a linear 
relationship between the pIC50 values against mPrP and the molecular descriptors, using 
ordinary least squares (OLS) algorithm in the QSARINS (QSAR-Insubria) software . 
For selecting the best model, the equations were ordered by QSARINS, showing the optimum 
models according to R2 (the highest value is in correspondence with the good fitting of the 
model), Q2LOO (Leave One Out - for the highest values and comparable with R2, the model is 
robust), R2−Q2LOO (a lower value is indicative of the model stability) and RMSE (should be 
small and as close as possible between calculation of training, training prediction by LOO and 
external prediction series XGX). 
Assessment of lowest number of variables. We developed several MLR models with low 
multicollinearity between descriptors and good correlation with the modeled response. The 
generated population of models were plotted as mean values of R2 and Q2loo (with their 
standard deviations) versus the number of variables of the model, in order to evaluate the 
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performance of the models against their size and to avoid overfitted models. The values of R2 
and Q2loo rose as new descriptors and were added to the model. The highest values were 
achieved by the models of seven variables; however, the models with five variables showed 
very similar values with three less predictive variables (data not shown) XGX. We therefore 
selected five variables as optimal dimension to develop the final model. These are LogP, 
Molecular Weight (MW), No. of Sulfur atoms (Nsulfur), No. Tricyclic scaffold (Ntricyclic) and 
Molecular size (diameter, D).  
Internal validation strategies. In order to control the robustness of the model, we carried out 
internal validation strategies. First, we used the Q2loo criterion applying the technique of cross-
validation (CV), i.e., iteratively excluding a compound from the dataset (Leaving One Out, 
loo), and then calculating a model with the remaining compounds and making the prediction 
for the excluded molecule. If the internal predictions were good, the value of Q2loo was high 
and comparable with R2, so the model was considered internally stable and robust. However, a 
disturbance of a single compound might be too weak to show the real model robustness. 
QSARINS further includes a stronger technique: Leaving Many Out (lmo), which allowed 
studying the behavior of the model when a larger number of compounds (in this case 30% of 
the compounds) were excluded. The model was considered stable if the values 
of R2 and Q2 calculated for each iteration of the lmo experiment and their averages 
(R2lmo and Q2lmo) were comparable with the values of R2 and Q2LOO of the model. 
Validation of the model accordingly to the OECD principles (XGX to be decided XGX). 
Algorithm QSARINS is a friendly software that can validate the obtained model using OECD 
principles, in order to increase the confidence of the predictions. According to these principles, 
the model should have the following: (1) a defined endpoint; (2) an unambiguous algorithm; (3) 
a defined domain of applicability; (4) appropriate measures of goodness-of-fit, robustness and 
predictability; and (5) a mechanistic interpretation, if possible [274].  
Principle 1 is associated with the endpoint definition where it refers to a physicochemical, 
biological or pharmacological property that can be measured and, therefore, modeled. The aim 
of this principle is to ensure transparency in the measurement point predicted by a given model. 
The endpoint in this work was pIC50 of the compounds against moPrP. 
According to Principle 2, QSAR models can be expressed in the form of unambiguous 
algorithms, considering that the algorithm model is the way of relating the descriptors of the 
chemical structure and activity (endpoint of the model) through mathematical models or rules 
based on the knowledge developed by one or more experts. The used algorithm was a 
mathematical model of Multiple Linear Regression detailed in the previous section. 
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Insubria graph was used for DA (Principle 3). This was very useful to assess the reliability of 
the predictions of experimental compounds, lacking response, and to compare with the 
predictions of the database XGX. 
Following the Principle 4, the goodness of the fit was evaluated using the coefficient of 
determination R2 and a modified form R2adj that also evaluated the effectiveness by adding a 
new descriptor to the model. While the robustness was evaluated with internal validation 
strategies (see above).  
The mechanistic interpretation of the model (Principle 5), although it is not mandatory, it is 
very desirable. In our work, we developed a general interpretation of the model based on 
docking calculation XGX. 
 
-In order to demonstrate that the model was not the result of a chance correlation, we applied 
the Y-scrambling procedure. In this procedure, responses are placed randomly, so there was no 
correlation with the descriptors and, as a result, the performance of the models should decay 
drastically. In this case, if the model in the validation process was good, the values 
of R2 and Q2 of each iteration, and their averages (R2YS and Q2YS) must be lesser and lesser with 
respect to the values of the model. 
-In order to assess the model’s ability to predict new compounds, an external validation was 
carried out. The procedure was performed by applying the model equation obtained with the 
training set, a predictive dataset, i.e., excluding compounds that have never been used for the 
calculation model. Model performance was evaluated by different criteria such as RMSEext, Q2-
F1, Q2-F2, Q2-F3, r2M, Δr2m, CCC, and Golbraikh and Tropsha methods. 
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Supporting Information 
 
Table S1. Published papers relative to the database’s molecules 
Cell line References 
GT-FK 
 
• Kimura, T. et al. (2011) Synthesis of GN8 derivatives and evaluation of their 
antiprion activity in TSE- infected cells. Bioorg. Med.  Chem. LeJ. 21, 1502–7   
• Kimura, T. et al. (2011) Synthesis of 9-substituted 2,3,4,9-tetrahydro-1H-carbazole 
derivatives and evaluation of their anti-prion activity in TSE-infected cells. Eur. J. 
Med. Chem. 46, 5675–5679   
ScGT1 • Thuy, N.T.H. (2010), Investigation on anti-prion, neuroprotective and anti-
cholinesterase activities of acridine derivatives, National University of Singapore  
• Korth, C. et al. (2001) ticridine and phenothiazine derivatives as 
pharmacotherapeutics for prion disease. Proc. Natl. ticad. Sci. U. S. ti. 98, 9836–9841   
• Vogtherr, M. et al. (2003) tintimalarial drug quinacrine binds to C-terminal helix of 
cellular prion protein. J. Med. Chem. 46, 3563–4   
• lingenstein, R. et al. (2006) Similar structure-activity relationships of quinoline 
derivatives for antiprion and antimalarial effects. J. Med. Chem. 49, 5300–5308   
• Nguyen Thi, H.T. et al. (2008) tintiprion activity of functionalized 9-aminoacridines 
related to quinacrine. Bioorganic Med. Chem. 16, 6737–6746  
ScN2a • Gallardo-Godoy, A. et al. (2011) 2-timinothiazoles tis Therapeutic Leads for Prion 
Diseases. J. Med. Chem. 54, 1010–1021   
• Li, Z. et al. (2013) 2-timinothiazoles with Improved Pharmacotherapeutic Properties 
for Treatment of Prion Disease. ChemMedChem 8, 847–857   
ScN2a • Staderini, M. et al. (2013) A fluorescent styrylquinoline with combined therapeutic 
and diagnostic activities against Alzheimer’s and Prion diseases. ACS Med. ... 4, 
225–9 
cl3 • Staderini, M. et al. (2013) A fluorescent styrylquinoline with combined therapeutic 
and diagnostic activities against Alzheimer’s and Prion diseases. ACS Med. ... 4, 
225–9   
• Bongarzone, S. et al. (2010) Parallel Synthesis, Evaluation, and Preliminary 
Structure−AcTvity RelaAonship of 2,5-Diamino-1,4-benzoquinones as a Novel Class 
of Bivalent Anti-Prion Compound. J. Med. Chem. 53, 8197–8201   
• Bolognesi, M.L. et al. (2010) Discovery of a class of diketopiperazines as antiprion 
compounds. ChemMedChem 5, 1324–34   
• Bongarzone, S. et al. (2011) Hybrid lipoic acid derivatives to attack prion disease on 
multiple fronts. ChemMedChem 6, 601–5   
• Tran, H.N.A. et al. (2010) Synthesis and evaluation of a library of 2,5-bisdiamino-
benzoquinone derivaAves as probes to modulate protein–protein interactions in 
prions. Bioorg. Med. Chem. LeJ. 20, 1866–1868   
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Table S2. Database subgroups. 
 
Cell line Drug treatment 
No. of 
compounds EC50 range (µM) SE* 
GTFK GT-FK 3 days 11 0.51-8.54 0.01-0.36 
GT1 ScGT1 5 days 23 0.15-15.8 0.01-0.9 
N2aa ScN2a 3 days 59 0.05-10 n/a 
N2ab ScN2a 6 days 41 0.021-4.24 n/a 
cl3 ScN2a-cl3 5 days 85 0.051-15.644 0.007-0.42 
Standard error of mean, SE 
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